

**CME Supplement to:**

# Current Opinion in Ophthalmology

## **Dysfunctional Tear Syndrome: Dry Eye Disease and Associated Tear Film Disorders - New Strategies for Diagnosis and Treatment**

Co-chairs: Mark S. Milner, MD, Kenneth A. Beckman, MD, and  
Jodi I. Luchs, MD, on Behalf of the Cornea, External Disease, and  
Refractive Society (CEDARS) Dysfunctional Tear Syndrome Panel

Jointly provided by New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC

Original Release: January 16, 2017

Last Review: November 12, 2016

Expiration: January 31, 2018

This continuing medical education activity is supported through unrestricted educational grants from Alcon; Allergan, Inc; Bausch & Lomb Incorporated; Blythe; Oasis; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; TearLab Corporation; and TearScience.



# Current Opinion in Ophthalmology

Editor-in-Chief **Allen C Ho**, Wills Eye Institute and Thomas Jefferson University, Philadelphia, Pennsylvania, USA

## EDITORIAL BOARD

### Mark S Blumenkranz

Stanford University School of Medicine, USA

### Roy S Chuck

Montefiore Medical Center, USA

### Thomas A Ciulla

Indiana University, USA

### Borja F Corcostegui

Instituto de Microvanguardia Ocular, Spain

### Emmett T Cunningham Jr

California Pacific Medical Center and Stanford University School of Medicine, USA

### David R Guyer

New York University of Medicine, USA

### Edward A Jaeger

Wills Eye Hospital, USA

### Glenn J Jaffe

Duke University Eye Center, USA

### Arthur SM Lim

Gleneagles Hospital, Singapore

### Maureen G Maguire

Scheie Eye Institute, USA

### Timothy G Murray

Bascom Palmer Eye Institute, USA

### Carmen A Pullafito

University of Southern California School of Medicine, USA

### Christopher Rapuano

Wills Eye Hospital, USA

### Carl D Regillo

Wills Eye Hospital, USA

### Gisele A Soubrane

Clinique Ophthalmologique Universitaire, France

### William S Tasman

Wills Eye Hospital, USA

### Nicholas J Volpe

Northwestern University Feinberg School of Medicine, USA

### George Williams

Beaumont Eye Institute, USA

## 2017 CONTENTS

### JANUARY

#### Cataract surgery and lens implantation

Edited by Natalie A Afshari, University of California, San Diego, California, USA

### MARCH

#### Glaucoma

Edited by Donald L Budenz, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

### MAY

#### Retinal, vitreous and macular disorders

Edited by Brandon G Busbee, Tennessee Retina, Tennessee, USA and John W Kitchens, Retina Associates of Kentucky, Lexington, USA

#### Translational research

Edited by Jason Hsu, Mid Atlantic Retina, USA and Sunir J Garg, Mid Atlantic Retina, USA

### JULY

#### Refractive surgery

Edited by Jimmy K Lee, Montefiore Medical Centre, New York, USA

#### Corneal and external disorders

Edited by Shahzad I Mian, University of Michigan, USA

### SEPTEMBER

#### Ocular genetics

Edited by Alex Levin, Wills Eye Hospital, Philadelphia, USA

#### Pediatrics and strabismus

Edited by J Mark Engel, University Children's Eye Center, New Jersey, USA

#### Oculoplastic and orbital surgery

Edited by Richard C Allen, University of Iowa Hospitals and Clinics, Iowa, USA

### NOVEMBER

#### Neuro-ophthalmology

Edited by Dean M Cestari, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA

#### Ocular manifestations of systemic disease

Edited by Russell W Read, University of Alabama at Birmingham, USA

Literature Scanners P. Shah, D. Heath, T. Leong, K.M. Nyunt

\*2015 Journal Citation Reports® (Thomson Reuters, 2016)





# Current Opinion in Ophthalmology

*Current Opinion in Ophthalmology* (ISSN 1040-8738)

- *Current Opinion in Ophthalmology* (USPS No.: 005-198) is published bimonthly by Wolters Kluwer Health, Inc. and distributed in the US by Mercury Airfreight International, Inc., 365 Blair Road, Avenel, NJ 07001, USA. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to Current Opinion in Ophthalmology, PO Box 1610, Hagerstown, MD 21740.
- Advertisements, statements or opinions expressed in *Current Opinion in Ophthalmology* reflect the views of the advertiser or author(s) and are not the opinion of Wolters Kluwer Health, Inc. or the Editorial Board unless so stated. Readers are advised that methods and techniques described involving drug usage should be followed only in conjunction with drug manufacturer's own published literature.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

## Publication Staff Wolters Kluwer Health, Ltd.:

**Publisher** Daniel Hyde

**Managing Editor** Stephanie Fairbairn

**Editorial Coordinator** Christiana Adewale

**Production Manager** Kevin Maycroft

**Production Editor** Asha Ladwa

**Typeset:** Thomson Digital, Noida Special Economic Zone, Noida, India.

**Printed and bound:** Markono Print Media Pte Ltd, Singapore printed on chlorine-free, recyclable paper from sustainable forests, meeting the requirements of ISO 9706, ISO 14001 and ISO 9001.

**Indexing:** *Current Opinion in Ophthalmology* is indexed by Index Medicus Current Contents, Cumulative Index to Nursing & Allied Health Literature (CINAHL), Current Awareness in Biological Sciences (CABS), EMBASE/Excerpta Medica, and Ocular Resources, Computer-Scan.

## SUBSCRIPTION

Annual subscription rates: United States individuals \$807; rest of the world individuals \$807; United States institutions \$2693; rest of the world institutions \$2757. Online only subscriptions for institutions are available through Ovid ([www.ovid.com](http://www.ovid.com)).

- The Canadian GST tax of 7% will be added to the subscription price of all orders shipped to Canada. Wolters Kluwer Health, Inc. GST identification Number is 895524239.
- Publications Mail Agreement #1119672. Subscriptions outside United States must be prepaid.
- Prices include handling and shipping, but not VAT.

### Address for subscription information, orders, or change of address:

#### USA, Europe and others:

Wolters Kluwer Health, Inc.  
14700 Citicorp Drive,  
Bldg 3,  
Hagerstown,  
MD 21742  
USA  
Tel: 1-800-638-3030;  
Fax: 1-301-223-2320.

#### Japan:

Wolters Kluwer Health Japan Co. Ltd.,  
3-23-14 Hongo,  
Bunkyo-ku,  
Tokyo 113-0033,  
Japan  
Tel: 81-3-5689-5400;  
Fax: 81-3-5689-5402.

#### India, Bangladesh, Sri Lanka, Nepal and Pakistan:

Globe Publication Pvt. Ltd  
B-13, 3rd FL, A Block,  
Shopping Complex,  
Naraina Vihar, Ring Road,  
New Delhi 110028, India  
Tel: 91-11-257-70411;  
Fax: 91-11-257-78876.

**Prices subject to change without notice. Copies will be replaced without charge if the publisher receives a request within 90 days of the mailing date, both in the USA and worldwide.**

#### Contacts:

#### Customer Services:

Wolters Kluwer Health, Inc.  
14700 Citicorp Drive,  
Bldg 3,  
Hagerstown,  
MD 21742  
USA

#### Publishing Office:

Wolters Kluwer Health, Ltd.  
Citi Building, 41st Floor,  
25 Canada Square,  
Canary Wharf,  
London,  
E14 5LQ,  
UK

**Permissions:** Please go to the Journal website and click the "Permissions" link above the title of the paper in the abstract or html window for the relevant article. Alternatively send an email to [customer-care@copyright.com](mailto:customer-care@copyright.com)

**Translation Rights and Licensing queries,** email: [translationrights@wolterskluwer.com](mailto:translationrights@wolterskluwer.com) or [healthlicensing@wolterskluwer.com](mailto:healthlicensing@wolterskluwer.com)

**Advertising Enquiries,** For further information please visit [www.wkadcenter.com](http://www.wkadcenter.com) or contact Avia Potashnik Tel: +44 (0) 203197 6722. Email: [avia.potashnik@wolterskluwer.com](mailto:avia.potashnik@wolterskluwer.com).

**For Special Projects and Reprints (U.S./Canada),** contact Alan Moore, Director of Sales, Wolters Kluwer Health, Inc., Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, USA. Phone: +1 215 521 8638. E-mail: [alan.moore@wolterskluwer.com](mailto:alan.moore@wolterskluwer.com)

**For Special Projects and Reprints (non-U.S./Canada),** email: [healthlicensing@wolterskluwer.com](mailto:healthlicensing@wolterskluwer.com).



# Current Opinion in Ophthalmology

**OPEN** Open access article is available online.

---

## TABLE OF CONTENT

---

- 1 **OPEN** **Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment**  
*Mark S. Milner, Kenneth A. Beckman, Jodi I. Luchs, Quentin B. Allen, Richard M. Awdeh, John Berdahl, Thomas S. Boland, Carlos Buznego, Joseph P. Gira, Damien F. Goldberg, David Goldman, Raj K. Goyal, Mitchell A. Jackson, James Katz, Terry Kim, Parag A. Majmudar, Ranjan P. Malhotra, Marguerite B. McDonald, Rajesh K. Rajpal, Tal Raviv, Sheri Rowen, Neda Shamie, Jonathan D. Solomon, Karl Stonecipher, Shachar Tauber, William Trattler, Keith A. Walter, George O. Waring IV, Robert J. Weinstock, William F. Wiley, and Elizabeth Yeu*

## LEARNING METHOD AND MEDIUM

This educational activity consists of a supplement and fifteen (15) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 3.0 hours to complete.

## CONTENT SOURCE

This continuing medical education (CME) activity captures content from a series of meetings and web conferences conducted by the Cornea, External Disease, and Refractive Society Dysfunctional Tear Syndrome Panel in 2014 and 2015.

## ACTIVITY DESCRIPTION

The management of dysfunctional tear syndrome (DTS) has traditionally followed established guidelines based on disease severity. In recent years, however, there have been clinical advances that might allow refinement of the management of DTS based on a differential diagnosis of DTS subtypes. New diagnostic tests and treatments are now available to help inform decisions for DTS subtypes. New diagnostic techniques can be applied to the differential diagnosis of DTS in individual patients. Likewise, new treatment modalities can be incorporated into management plans to improve outcomes in patients with different DTS subtypes. The purpose of this activity is to update clinicians on new developments in diagnosis, treatment for patients with DTS, and the application of newer diagnostic tests and treatments for individual patients with DTS.

## TARGET AUDIENCE

This activity is intended for ophthalmologists and other eye care professionals.

## LEARNING OBJECTIVES

*Upon completion of this activity, learners will be better able to:*

- Outline the potential roles of new diagnostic tests for DTS
- Discuss recent developments in treatments for DTS
- Apply available evidence on diagnostic techniques and clinical assessment tools for the differential diagnosis of DTS subtypes
- Design management plans for patients using treatment modalities that address the underlying disease mechanisms of DTS subtypes

## ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of **New York Eye and Ear Infirmary of Mount Sinai** and MedEdicus LLC. The **New York Eye and Ear Infirmary of Mount Sinai** is accredited by the ACCME to provide continuing medical education for physicians.

**Curr Opin Ophthalmol** 2017, 28 (Suppl 1):1–47

DOI:10.1097/ICU.0000000000000355



*In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai "Accreditation with Commendation," for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.*

## AMA CREDIT DESIGNATION STATEMENT

The **New York Eye and Ear Infirmary of Mount Sinai** designates this enduring material for a maximum of 3.0 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## GRANTOR STATEMENT

This continuing medical education activity is supported through unrestricted educational grants from Alcon; Allergan; Bausch & Lomb Incorporated; Blythe; Oasis; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; TearLab Corporation; and TearScience.

## DISCLOSURE POLICY STATEMENT

It is the policy of **New York Eye and Ear Infirmary of Mount Sinai** that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). **New York Eye and Ear Infirmary of Mount Sinai** has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

## DISCLOSURE ATTESTATION

The contributing physicians listed at the end of this monograph attested to the following:

- (1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- (2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- (3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

Full disclosure of faculty/planners and their commercial relationships, if any, can be found at the end of the manuscript before the references.

## OFF-LABEL DISCUSSION

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

## For Digital Editions

### System Requirements:

If you are viewing this activity online, please ensure the computer you are using meets the following requirements:

## New Strategies for Diagnosis and Treatment of DTS

---

- **Operating System:** Windows or Macintosh
- **Media Viewing Requirements:** Flash Player or Adobe Reader
- **Supported Browsers:** Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- **A good Internet connection**

### **New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies**

<http://www.nyee.edu/health-professionals/cme/enduring-activities>

**CME Provider Contact Information:** For questions about this activity, call 212-979-4383.

### **TO OBTAIN AMA PRA CATEGORY 1 CREDIT™**

To obtain *AMA PRA Category 1 Credit™* for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Return via mail to Kim Corbin, Director, ICME, **New York**

**Eye and Ear Infirmary of Mount Sinai**, 485 Madison Avenue, 17th Floor, New York, NY 10003 or fax to (212) 353-5703. Your certificate will be mailed to the address you provide on the Activity Evaluation/Credit Request form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity.

Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to <http://tinyurl.com/DTSCME>. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to two times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

### **DISCLAIMER**

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of **New York Eye and Ear Infirmary of Mount Sinai**; MedEdicus LLC; Alcon; Allergan; Bausch & Lomb Incorporated; Blythe; Oasis; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; TearLab Corporation; TearScience; or *Current Opinion in Ophthalmology*.



## Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment

Mark S. Milner<sup>a,b,\*</sup>, Kenneth A. Beckman<sup>c,d,\*</sup>, Jodi I. Luchs<sup>e,f,\*</sup>,  
 Quentin B. Allen<sup>g</sup>, Richard M. Awdeh<sup>h</sup>, John Berdahl<sup>i</sup>, Thomas S. Boland<sup>j,k</sup>,  
 Carlos Buznego<sup>h</sup>, Joseph P. Gira<sup>l</sup>, Damien F. Goldberg<sup>m,n</sup>, David Goldman<sup>o</sup>,  
 Raj K. Goyal<sup>p,q</sup>, Mitchell A. Jackson<sup>r,s</sup>, James Katz<sup>t</sup>, Terry Kim<sup>u</sup>,  
 Parag A. Majmudar<sup>p,v</sup>, Ranjan P. Malhotra<sup>w</sup>, Marguerite B. McDonald<sup>x,y,z,aa</sup>,  
 Rajesh K. Rajpal<sup>bb</sup>, Tal Raviv<sup>cc</sup>, Sheri Rowen<sup>dd,ee</sup>, Neda Shamie<sup>ff,gg</sup>,  
 Jonathan D. Solomon<sup>hh</sup>, Karl Stonecipher<sup>ii</sup>, Shachar Tauber<sup>jj</sup>,  
 William Trattler<sup>h</sup>, Keith A. Walter<sup>kk</sup>, George O. Waring IV<sup>ll,mm</sup>,  
 Robert J. Weinstock<sup>nn,oo</sup>, William F. Wiley<sup>pp</sup>, and Elizabeth Yeu<sup>qq</sup>

Dysfunctional tear syndrome (DTS) is a common and complex condition affecting the ocular surface. The health and normal functioning of the ocular surface is dependent on a stable and sufficient tear film. Clinician awareness of conditions affecting the ocular surface has increased in recent years because of expanded research and the publication of diagnosis and treatment guidelines pertaining to disorders resulting in DTS, including the Delphi panel treatment recommendations for DTS (2006), the International Dry Eye Workshop (DEWS) (2007), the Meibomian Gland Dysfunction (MGD) Workshop (2011), and the updated Preferred Practice Pattern guidelines from the American Academy of Ophthalmology pertaining to dry eye and blepharitis (2013). Since the publication of the existing guidelines, new diagnostic techniques and treatment options that provide an opportunity for better management of patients have become available. Clinicians are now able to access a wealth of information that can help them obtain a differential diagnosis and treatment approach for patients presenting with DTS. This review provides a practical and directed approach to the diagnosis and treatment of patients with DTS, emphasizing treatment that is tailored to the specific disease subtype as well as the severity of the condition.

<sup>a</sup>Yale University School of Medicine, New Haven, <sup>b</sup>The Eye Center of Southern Connecticut, Hamden, Connecticut, <sup>c</sup>Ohio State University, Columbus, <sup>d</sup>Comprehensive Eye Care of Central Ohio, Westerville, Ohio, <sup>e</sup>Hofstra Northwell School of Medicine, Hempstead, <sup>f</sup>South Shore Eye Care, Wantagh, New York, <sup>g</sup>Florida Vision Institute, Jupiter, <sup>h</sup>Bascom Palmer Eye Institute, Florida International University, and Center for Excellence in Eye Care, Miami, Florida, <sup>i</sup>Vance Thompson Vision, Sioux Falls, South Dakota, <sup>j</sup>Northeastern Eye Institute, Scranton, <sup>k</sup>Commonwealth Medical College, Scranton, Pennsylvania, <sup>l</sup>Ophthalmology Consultants, St. Louis, Missouri, <sup>m</sup>Jules Stein Eye Institute, Los Angeles, <sup>n</sup>Wolstan & Goldberg Eye Associates, Torrance, California, <sup>o</sup>Palm Beach Gardens, Florida, <sup>p</sup>Rush University Medical Center, Chicago, <sup>q</sup>Chicago Eye Specialists, <sup>r</sup>University of Chicago Hospitals, Chicago, <sup>s</sup>Jacksoneye, Lake Villa, <sup>t</sup>Midwest Center for Sight, Des Plaines, Illinois, <sup>u</sup>Duke Eye Center, Durham, North Carolina, <sup>v</sup>Chicago Cornea Consultants, Ltd, Hoffman Estates, Illinois, <sup>w</sup>Washington University Department of Ophthalmology and Ophthalmology Associates, St. Louis, Missouri, <sup>x</sup>NYU Langone Medical Center, New York, New York, <sup>y</sup>Tulane University School of Medicine, New Orleans, Louisiana, <sup>z</sup>Ophthalmic Consultants of Long Island, Lynbrook, New York, <sup>aa</sup>The Center for Ocular Surface Excellence of New Jersey, Woodland Park, New Jersey, <sup>bb</sup>Georgetown University Medical Center, George Washington University Medical Center, Washington, DC, <sup>cc</sup>New York Eye and Ear Infirmary of Mount Sinai and Eye Center of New York, New York, New York, <sup>dd</sup>NVision EyeCenters of Newport Beach, Newport Beach, California, <sup>ee</sup>University of Maryland, Baltimore, Maryland, <sup>ff</sup>Advanced Vision Care, Century City, California, <sup>gg</sup>Keck School of Medicine, University of Southern California, Los Angeles, <sup>hh</sup>Bowie Vision Institute, Bowie, Maryland, <sup>ii</sup>University of North Carolina and TLC Laser Eye Centers, Greensboro, North Carolina, <sup>jj</sup>Mercy Eye Specialists, Springfield, Missouri, <sup>kk</sup>Wake Forest University, Winston-Salem, North Carolina, <sup>ll</sup>Storm Eye Institute and Magill Vision Center, Medical University of South Carolina, Charleston, <sup>mm</sup>Clemson University, Mt. Pleasant, South Carolina, <sup>nn</sup>University of South Florida, Tampa, <sup>oo</sup>The Eye Institute of West Florida, Largo, Florida, <sup>pp</sup>Cleveland Eye Clinic, Clear Choice Custom LASIK Center, Brecksville, Ohio, and <sup>qq</sup>Eastern Virginia Medical School and Virginia Eye Consultants, Norfolk, Virginia, USA

Correspondence to Mark S. Milner, MD, FACS, The Eye Center of Southern Connecticut, 2880 Old Dixwell Ave, Hamden, CT 06518, USA. Tel: +1 203 248 6365; fax: +1 203 230 1520; e-mail: Eyecentermm@hotmail.com

\*Mark S. Milner, Kenneth A. Beckman, and Jodi I. Luchs are co-chairs.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI:10.1097/O1.icu.0000512373.81749.b7




## INTRODUCTION

Management of dysfunctional tear syndrome [1] (DTS) is often a source of frustration for eye care professionals and patients. Several factors create challenges in the diagnosis and management of DTS. These include the lack of correlation between signs and symptoms [2,3], overlap among symptoms of different DTS subtypes (Fig. 1) [2], complex etiology, poorly understood pathophysiology of DTS-associated conditions, historically limited range of diagnostic tests, limited number of US Food and Drug Administration-approved treatment options, and the potential progressive nature of the condition. Poor patient compliance with follow-up visits also contributes significantly to the difficulties encountered when treating patients with DTS.

Clinician awareness of conditions affecting the ocular surface has increased in recent years because of new clinical research and the publication of diagnostic and treatment guidelines for disorders resulting in DTS. These guidelines include the Delphi

panel treatment recommendations for DTS (2006) [1], the International Dry Eye WorkShop (DEWS) (2007) [4], the International Workshop on Meibomian Gland Dysfunction (MGD) (2011) [5], and the updated Preferred Practice Pattern guidelines from the American Academy of Ophthalmology pertaining to dry eye and blepharitis (2013) [6,7]. These guidelines generally recommend treatment based on the severity of the condition for the subtypes of DTS. New diagnostic methods and pharmacologic treatments that can be used to further inform severity-based decisions to help better manage DTS and associated masquerading conditions have since become available.

To combine the latest evidence-based approaches for diagnosis and management of DTS with existing guideline-based approaches, we convened a specialty panel with experts from the Cornea, External Disease, and Refractive Society (CEDARS), hereafter referred to as the DTS Panel, to provide a clinical approach to using the latest diagnostic tools and guidelines to direct treatment that is tailored to the specific disease subtype(s). The evidence for a comprehensive range of diagnostic methods, including recently developed techniques, and a comprehensive review of established and new treatment modalities for managing DTS and its subtypes is reviewed herein. Case studies are included to demonstrate how the new approaches can be applied to specific clinical scenarios.



**FIGURE 1.** Overlap of symptoms in dysfunctional tear syndrome (DTS) subtypes. There is a substantial overlap in the patient-reported symptoms of the types of DTS. Patients with subtypes of aqueous deficiency, blepharitis/meibomian gland dysfunction (MGD) – evaporative and nonevaporative – goblet cell deficiency/mucin deficiency, and exposure-related forms of DTS, including exposure keratopathy, may report symptoms of ocular discomfort, dryness, burning/stinging, grittiness or a foreign body sensation, photophobia, and blurred/fluctuating vision. Clinical evaluation with a battery of assessments and diagnostic techniques are needed for a differential diagnosis.

## DIAGNOSIS-BASED INDIVIDUALIZED TREATMENT APPROACH

The primary goal of the DTS Panel was to provide an approach for improved outcomes in the treatment of patients with DTS through differential diagnosis and directed treatment. Toward this end, we started by defining DTS as a disorder of the tear film in quality and/or quantity, which is caused by a range of etiologies and involves abnormalities in one or more components of the tear film, resulting in a constellation of signs and symptoms affecting the ocular surface. Any alteration in the quantity and/or quality of the tear film can result in DTS, a chronic condition with multiple subtypes that include dry eye disease (DED) and associated tear film disorders. It has been shown that without proper diagnosis and management, DTS can result in profound degradation in quality of life and visual function-based activities (i.e., reading, driving, and computer use), the extent of which correlates with the severity of the condition [8]. Additionally, DTS can negatively affect surgical outcomes, such as those of cataract and refractive surgical procedures [9,10]. The



overlap and frequent comorbidity of DED and other conditions affecting the quantity or quality of the tear film require careful examination of patients with DTS. Achieving a differential diagnosis and classification into specific disease-state subtypes allows a directed, individualized treatment approach.

Four main subtype classifications used by the DTS Panel approach are as follows: first, aqueous deficiency; second, blepharitis/MGD (evaporative and nonevaporative); third, goblet cell deficiency/mucin deficiency; and fourth, exposure-related DTS (Fig. 2). Following the clinical assessment and evaluation of a patient with DTS, each patient can be classified into one or more of the disease-state subtypes (the presence of multiple subtypes within a patient is common). Identifying and treating other conditions or ‘DTS co-conspirators’ that may masquerade as or contribute to the signs and symptoms of DTS are equally important.


This approach can be used with new and current patients reporting DTS symptoms (e.g., ocular dryness, discomfort, burning/stinging, and grittiness/foreign body sensation), patients reporting a fluctuation in vision or other nonspecific visual obscurations, referred patients with a history of dry eye or blepharitis, and patients who are being evaluated for laser vision correction or cataract surgery, particularly those who may use multifocal or other premium intraocular lenses.

Published information supporting the use of new diagnostic tests, recently approved therapies,

and the potential role of novel or investigational therapies for patients with DTS was evaluated on a tiered basis, ranging from level I through level III, depending on the rigor of the study design, with level I denoting evidence from a randomized controlled clinical trial (or equivalent), level II indicating evidence from a controlled study that was not randomized or involved a cohort-based study at one or more centers, and level III indicating case studies, published meeting abstracts, or expert opinions. The DTS Panel compiled the published literature (i.e., reports of clinical trials, case reports, and meeting presentations) and presented the information for a review discussion at panel working meetings, which used voting to achieve a consensus. The studies cited were deemed the most relevant to the individual topic.

### Step 1: patient history

Table 1 summarizes the types of information that should be collected from a patient with potential DTS. Recording a thorough medical and ocular history, including surgical history, provides the initial context for evaluating the patient. Current and past use of systemic and ocular medications is also important to capture at this stage. Past or current therapy for conditions such as DED, blepharitis, and any allergies, even treatments that were regarded as ‘failures’, should be noted and queried. The timing, frequency, and severity of the chief complaints or symptoms reported by the patient also



**FIGURE 2.** Flow chart of the DTS Panel clinical approach. A differential diagnosis is achieved through the DTS Panel clinical approach through examination of patients via a series of clinical assessments and diagnostic techniques. Patients with dysfunctional tear syndrome (DTS) are classified to one or more of the four DTS subtypes: aqueous deficiency, blepharitis/meibomian gland dysfunction, goblet cell deficiency/mucin deficiency, and exposure-related DTS. Treatment options are determined on the basis of the specific DTS subtype(s) identified, thus allowing for a directed treatment approach.

**Table 1.** Patient history

Important information to collect from patients with potential DTS
Medical history
Ocular history, including surgical history and contact lens use
Systemic medications
Ocular medications
Allergies
Chief complaints or current symptoms
Prior and current therapy for treatment of DTS

DTS, dysfunctional tear syndrome.

offer initial insight into the classification of the DTS subtype(s).

### Step 2: preliminary assessments

A technician or other member of the office staff may perform the initial assessment of a patient with potential DTS; however, in some practices, the clinician may conduct this part of the evaluation. Table 2 lists the preliminary assessments recommended by the authors at this point. Consistency in the conduct of each of the assessments among staff members is critical because the results of the diagnostic tests at the initial visit will serve as the baseline for comparison with follow-up visits. Patients with DTS often report blurred vision or intermittent distortion of vision [11]. As such, evaluation of the patient's visual acuity, with and without his or her current corrective glasses or lenses, and an assessment of any refraction necessary to achieve best-corrected visual acuity is an important portion of the preliminary assessment. In addition to assessment of visual acuity, patients should be queried regarding the nature and frequency of any reports of

**Table 2.** Preliminary assessments performed by the technician or clinician

Clinical assessments and diagnostic measures used as part of the preliminary examination
Visual acuity (with and without glasses/lenses)
Refraction evaluation – best-corrected visual acuity
Administer a questionnaire (e.g., OSDI and SPEED)
Tear osmolarity <sup>a</sup> – must be conducted before disturbing the eye
Assess inflammatory markers present in the tear film (MMP-9) <sup>a</sup>
Schirmer test with and/or without anesthesia (clinician preference)

MMP-9, matrix metalloproteinase-9; OSDI, Ocular Surface Disease Index; SPEED, Standard Patient Evaluation of Eye Dryness.  
<sup>a</sup>If available.

fluctuation in vision. Once the visual acuity and refraction assessments are complete, the patient may be assessed using a questionnaire.

Prior to conducting any additional assessments involving contact with the ocular surface, tear film osmolarity can be evaluated if the necessary equipment is available [12–15]. Following this evaluation, the relative level of ocular inflammation (common among all subtypes of DTS), as measured by quantifying the level of inflammatory mediator markers, such as matrix metalloproteinase (MMP)-9, in the tear film can be assessed if the laboratory equipment or diagnostic device is available [16–18]. Finally, the patient's relative tear volume and secretion should be measured via a Schirmer strip test [15]. Depending on the patient's response to contact with the ocular surface as part of the preliminary assessments, some of the assessments may need to be conducted at a follow-up visit if significant reflex tearing is observed. The 'Diagnostics and clinical assessments' section presents additional detailed information pertaining to the description and interpretation of the diagnostic tests described previously.

### Step 3: primary assessments

The physician or lead clinician generally conducts the primary assessments and tests used in the diagnosis of DTS. Table 3 presents a summary description of the following primary assessments and diagnostic procedures that are recommended at this stage:

- (1) Conduct a thorough review of the patient's medical, ocular, and surgical history as well as the nature and frequency of past and current medication use, including any changes that have been noted since a prior visit.
- (2) Discuss the patient's responses to the questionnaire or other instrument to help clarify the relative frequency and timing (diurnal pattern) of DTS-related symptoms and any effect on daily activities, such as reading, driving, or computer use. During the review of the patient's medical information and discussion of questionnaire responses, behaviors that may contribute to ocular irritation, such as mucus fishing, may be observed. The responses to the questionnaire may provide insight regarding the severity level of the DTS as well.
- (3) Conduct an external examination of the patient's skin, adnexa, and eyelids to provide additional insight toward a differential diagnosis. Express the meibomian glands for each eyelid. Emphasis on the eyelid margin, lashes, and

**Table 3.** Primary assessments and diagnostic procedures performed by the clinician

Clinical assessments and diagnostic measures used by the clinician
Review of patient's medical and ocular history, including responses to questionnaire
Review of past/current medication use
External examination: particular emphasis on the lid, lid closure, and blinking (complete and incomplete)
Slit-lamp examination
Lids and lashes (lids should be everted)
Anterior segment – ocular surface
Tear meniscus
Instill fluorescein dye; observe staining pattern on cornea and TBUT
Instill lissamine green and/or rose bengal; observe staining pattern on the conjunctiva and cornea
Evaluation and expression of meibomian glands

TBUT, tear break-up time.

lid closure is important to note any anatomic defects, malposition of the tissue, partial or incomplete blinking, debris, and alteration of the meibum or inflammation of the orifices of the meibomian glands (Fig. 2).

- (4) Conduct a slit-lamp examination to detect abnormalities that are essential in determining a differential diagnosis of DTS. The eyelids, including features of the anterior and posterior lid margin, and lashes, should be examined carefully. Additionally, the upper lids should be everted to allow direct visualization of the tarsal conjunctiva. Observe structures of the anterior segment, noting the relative severity of any discernible inflammation or other abnormalities associated with ocular structures. The relative height of the inferior tear meniscus should also be evaluated at this step of the examination. Practitioners may note a normal or decreased tear meniscus during a standard examination; a tear meniscus height of less than 0.3 mm is considered abnormal [15]; however, in the experience of the authors, clinicians may often estimate the tear meniscus and make a subjective determination about whether it is decreased.
- (5) Instill fluorescein dye (2–5  $\mu$ l of 1 or 2% sodium fluorescein or a commercially available fluorescein preparation) via micropipette, a device designed to precisely deliver a small amount of liquid, or through the application of physiological saline-moistened fluorescein strips to the ocular surface for visualization of the tear film and any damage to the corneal

epithelium when viewed through the slit-lamp with cobalt blue light and the addition of a Wratten (yellow) filter, if available. Waiting approximately 2 min following the application of the dye to the ocular surface may enhance the visible staining pattern [6]. In general clinical practice, specialty devices, such as a micropipette and slit-lamp filter, may not be available. Ocular surface staining may still be observed through the application of dye via a fluorescein strip or a commercially available fluorescein preparation and direct illumination with the slit-lamp. The severity and location/pattern of corneal fluorescein staining should be carefully noted.

- (6) Assess the tear break-up time (TBUT) during this part of the examination by measuring the time between the patient's last blink and the appearance of the first patch of discontinuity in the tear film. Replicating the test two to three times per eye will provide a more reliable result to determine whether the patient has a rapid TBUT (<10 s) [6,19]. Application of vital stains, including lissamine green and/or rose bengal, allows for a similar level of observation of the integrity of the conjunctiva and cornea [20,21]. The 'Diagnostics and clinical assessments' section presents additional detailed information pertaining to the description and interpretation of the diagnostic tests described previously.

#### Step 4: additional diagnostic tests

Based on the patient history, clinical findings, and results of the previous diagnostic procedures, additional testing may be necessary or useful in diagnosing DTS. Table 4 briefly describes additional tests that may be used. Although specialized equipment may be needed to conduct certain procedures, other tests may need only basic materials. Corneal topography (keratography) may be included as a diagnostic test in a DTS evaluation, particularly if a patient reports distortion of vision. Optical coherence tomography (OCT) may be used to provide a quantitative assessment of the tear meniscus. Double-pass wave front assessment may be used to provide a functional analysis of the optical characteristics of the tear film based on the light scatter. Interferometry and meibography are other tests that may be conducted, as necessary, if the equipment is available to provide information pertaining to the outer lipid component of the tear film and the relative anatomy of the meibomian glands present within the lids. A simple evaluation of a patient's

**Table 4.** Additional assessments and diagnostic procedures

**Clinical assessments and diagnostic measures that provide additional information that may be helpful in determining a differential diagnosis**

Corneal sensation
Corneal topography
Tear film imaging
Evaluation of the tear film lipid layer
OCT: evaluation of the tear meniscus
Functional tear analysis light scatter
Imaging of the meibomian glands
Serum antibody biomarkers and/or other serological tests
Cultures from the ocular surface or associated tissue

OCT, optical coherence tomography.

corneal sensation (normal, decreased, or none) may be determined through the use of a cotton swab, tip of a tissue, nonwaxed dental floss, or a similar substitute.

In conjunction with the patient’s medical history and clinical findings, serologic testing provides insight or confirmation of a diagnosis of systemic conditions, such as Sjögren syndrome, through the presence of autoantibody biomarkers. Cultures and samples from the ocular surface or adnexa can be sent for laboratory analysis or testing onsite to investigate the presence of pathogenic organisms or elevated markers for other ocular conditions [e.g., immunoglobulin E (IgE) and lactoferrin]. The ‘Diagnostics and clinical assessments’ section presents additional detailed information pertaining to the description and interpretation of the diagnostic tests described previously.

**Step 5: differential diagnosis**

Dysfunction of the tear film is a common condition that causes patients to seek ophthalmic care. ‘Dry eye’ is a term used to discuss a lack of tear production; however, the term is often used to refer to any tear disorder. Dry eye, a common cause of DTS, is currently estimated to affect 2–14.4% of the US population [22]. Extensive research has been conducted in the area of DED over the past several decades. The definition of DED has evolved based on understanding of the pathogenesis of the condition. The DEWS 2007 report [4] defined dry eye as ‘a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the

ocular surface; it is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface’.

The prevalence of blepharitis/MGD (evaporative and nonevaporative), another common cause of DTS that frequently alters the functionality of the tear film, has also been difficult to accurately determine. The results of recent surveys conducted among ophthalmologists and optometrists indicate that blepharitis has been observed in 37–47% of patients [23]. Additionally, a recent assessment of patients preparing to undergo cataract surgery indicated that 59% of patients were diagnosed with blepharitis [24]. MGD is a common cause of excess evaporation of the tear film, resulting in dry eye. Analysis of the frequency of distribution of dry eye subtypes indicates that MGD is one of the most common underlying conditions, with signs of MGD present in 86% of a mixed patient population with dry eye [25].

To achieve the primary goal of the DTS Panel of using a diagnosis-based approach to improve patient outcomes, all the evidence from the patient’s medical history information, reported symptoms and effect on daily activities, clinical assessments, and diagnostics must be evaluated. A patient diagnosed with DTS can be classified with one or more of the four main disease-state subtypes described subsequently. Table 5 describes the primary characteristics and clinical findings that will aid in the identification of the DTS subtype(s) present in a particular patient. Additionally, it is important to recognize and treat any DTS co-conspirator conditions that may be masquerading as DTS or exacerbating a patient’s signs and symptoms.

**Aqueous deficiency**

Aqueous tear deficiency is primarily identified as a volumetric condition. Aqueous-deficient dry eye (ADDE) is one of the primary subtypes of DED, as recognized by the etiologic classifications system presented in the DEWS report [4]. Aqueous deficiency is characterized by a reduction in the secretions from the lacrimal gland (main and accessory glands) that form the basis of the bulk aqueous component of the tear film. The reduction in the aqueous secretions may be due to dysfunction or destruction of the lacrimal gland or a scarring/blockage of the lacrimal gland ductules, which prohibits the aqueous secretions from reaching the ocular surface, generally resulting in a reduced tear lake and elevated tear film osmolarity, or inflammation [26–28]. Because of the regulatory neuronal control of tear secretion, neurogenic inflammation – associated with injury, surgery,



**Table 5.** Differential diagnosis

Primary characteristics that may be observed for each of the main subtypes of DTS			
Aqueous tear deficiency	Blepharitis/MGD (evaporative or nonevaporative)	Goblet cell deficiency/mucin deficiency	Exposure-related DTS
Decreased Schirmer score (<10 mm after 5 min)	Anterior blepharitis: lid margin erythema; lid debris/scurf; collarettes; cylindrical sleeve at base of lashes ( <i>Demodex</i> )	Rapid TBUT (<10 s)	Lid dysfunction or malposition
Decreased tear meniscus (<0.3 mm height)	Posterior blepharitis/MGD: plugged meibomian gland orifices; thickened and/or turbid meibomian gland secretions; lid margin erythema and/or telangiectasia	Conjunctival scarring	Poor or partial blink
Keratoconjunctivitis sicca pattern of ocular surface staining (see Tables 7 and 8)	Rapid TBUT (<10 s)	Decreased goblet cell density (evaluated via biopsy or impression cytology)	Lagophthalmos

Not all characteristics may be present in all patients. DTS, dysfunctional tear syndrome; MGD, meibomian gland dysfunction; TBUT, tear break-up time.

systemic conditions, and topical agents that decrease corneal sensation – may result in reduced activity of the lacrimal gland [4,22]. A further subclassification of ADDE is defined according to the presence or absence of a diagnosis of the patient with Sjögren syndrome [29–31].

Patients classified with aqueous deficiency generally have a reduced Schirmer score of less than 10 mm on the test strip. A score of less than 5 mm is not uncommon in patients with moderate-to-severe aqueous deficiency [19]. During the examination, a decreased tear meniscus is typically observed in patients with aqueous deficiency. Upon application of fluorescein and/or lissamine green/rose bengal dye to the ocular surface, a staining pattern characteristic of keratoconjunctivitis sicca is often present. The extent of staining will generally correlate with the severity of the aqueous deficiency [15,32].

### **Blepharitis/meibomian gland dysfunction (evaporative and nonevaporative)**

As with DED, extensive basic and clinical research has been conducted in an effort to understand the pathogenesis of the various forms of blepharitis, particularly MGD. In a 2011 published report [5], the International Workshop on Meibomian Gland Dysfunction defined MGD as ‘a common disorder that may be asymptomatic or give rise to symptoms, either confined to the affected lids, or arising from MGD-related ocular surface disease, including evaporative dry eye (EDE); it can also exacerbate ADDE’.

Blepharitis is a condition that typically involves chronic inflammation of the eyelids, particularly the eyelid margin. The subtypes of blepharitis have been classified via a number of systems.

Classification based on anatomic position, relative to the eyelid margin, includes anterior blepharitis affecting the skin of the eyelid, eyelashes, and eyelash follicles and posterior blepharitis affecting the meibomian glands and meibomian gland orifices. The clinical classification of anterior blepharitis includes the categories seborrheic, atopic, staphylococcal, herpetic, parasitic (i.e., *Demodex*), and fungal. As with other subtypes of DTS, combinations of the subtypes of blepharitis may occur simultaneously in patients [33,34]. The overgrowth of staphylococcal or other bacteria on the anterior portion of the lid margin may result in erythema, scaling, and crusting, with folliculitis, collarettes, or pustules present at the base of the lashes [33]. Several forms of anterior blepharitis are identified by greasy scaling/scurf around the lid margin for seborrheic, and sleeves at the base of lashes for *Demodex*. Other forms may be identified via culture [7].

Evaporative dry eye is the second primary subtype of DED, as defined by the etiologic classification system presented in the DEWS report [4]. Estimates indicate that EDE is the most common form of DED [25]. Excessive loss of the bulk aqueous component of the tear film (normally secreted by the lacrimal gland, due to an insufficient or abnormal outer lipid component of the tear film, is the primary characteristic of evaporative tear disease [4]. Meibum, which is released from the meibomian glands present in the upper and lower lids and assisted by the blinking process, creates a thin oily layer over the bulk aqueous aspect of the tear film, thereby reducing evaporation. A lack of even distribution of the tear film due to insufficient production of soluble and membrane-bound mucins [35] or alterations in

the nature or quality of meibum may result in a rapid TBUT, exposing the ocular surface to desiccating stress [36–38].

The outermost component of the tear film, the lipid layer, plays a critical role in the stability of the tear film. Alterations in the posterior lid margin, including the development of prominent blood vessels or telangiectasia, thickened or turbid secretions of the meibomian glands, and plugged gland orifices, are primary characteristics of MGD [7,39]. Changes in the tear film lipids or meibomian glands observed through interferometry and meibography can also provide valuable insight into the differential diagnosis of blepharitis/MGD. A focused examination of the anterior and posterior portions of the lid margin and manual expression of meibomian glands are important components for diagnosing blepharitis/MGD [7]. Although EDE associated with MGD is a common condition [25], the blepharitis/MGD subtype of the DTS Panel approach includes both evaporative and nonevaporative manifestations of the condition.

#### **Goblet cell deficiency/mucin deficiency**

Patients with goblet cell loss suffer from a subsequent reduction in mucin production. Attached mucin glycoproteins at the cell surface and soluble mucins interact with the aqueous component to affect the surface tension of the tear film and improve the spreading of tears across the ocular surface. Goblet cell loss and/or mucin deficiency affects the stability of the tear film. Although a rapid TBUT (<10s) is frequently observed in patients with MGD, rapid TBUT is also observed in patients with goblet cell loss and/or mucin deficiency [40–42].

The primary characteristics of patients with goblet cell loss are a recognizable deficiency in goblet cell density (observed directly via impression cytology or conjunctival biopsy or inferred through observation of conjunctival inflammation and scarring [42]) and subsequent deficiency of mucin production. If available, in-vivo confocal microscopy can also be used to evaluate goblet cells and inflammation of the conjunctiva [43]. Goblet cell deficiency may result from or be associated with cicatricial conjunctivitis, such as Stevens–Johnson syndrome, toxic epidermal necrolysis, pemphigoid, thermal and chemical injuries, vitamin A deficiency, contact lens wear, and even epidemic keratoconjunctivitis (EKC). Additionally, patients with chronic chemical exposure or who habitually administer multiple ocular medications, such as glaucoma drops, may experience goblet cell loss [4,42,44–47].

#### **Exposure-related dysfunctional tear syndrome**

Excessive drying of the ocular surface due to anatomic defects, improper functioning, or malposition of the eyelids may result in exposure-related DTS. Failure of the eyelids to fully close or abnormal lid positioning exposes portions of the cornea to the external environment for an extended duration [48]. Exposure of the ocular surface beyond the interblink interval can initiate or exacerbate dysfunction of the tear film [49,50].

Observation of the positioning of the lids during the external examination, in conjunction with a careful review of the patient's medical history and chief complaints, can assist in a differential diagnosis of exposure keratopathy. Patients with Bell palsy, Parkinson disease, or other neurologic disorders may exhibit an incomplete or partial blink. Additionally, rigid contact lens wearers may have a reduced blink reflex in an effort to avoid disrupting the lens position. Characteristic staining patterns on the ocular surface are observed when dye is applied during a slit-lamp examination, thereby assisting in the diagnosis of exposure-related DTS due to conditions such as lagophthalmos. Lagophthalmos may be associated with complications resulting from blepharoplasty, scarring of the eyelid, thyroid eye disease, and other conditions [42,51].

#### **Dysfunctional tear syndrome co-conspirators**

The term 'DTS co-conspirators' is proposed to refer to conditions affecting the tear film and ocular surface that may masquerade or exacerbate DTS. DTS co-conspirators include superior limbic keratoconjunctivitis (SLK), medicamentosa, Thygeson superficial punctate keratitis, mucus fishing syndrome, contact lens-related toxicity, chemical toxicity, allergic/atopic conjunctivitis, conjunctivochalasis, floppy lid syndrome, and corneal hyperalgesia. Ocular allergy is a common DTS co-conspirator that often shares similar signs and symptoms with DED. Testing, such as in-office skin testing and tear film IgE analysis, may help identify this condition [52,53]. A thorough patient history review and examination are required to differentiate these DTS co-conspirators from one or more of the four main subtypes of DTS. Identification of the DTS co-conspirators is critical in the management of DTS because patients often present with persistent signs and symptoms despite general treatment for one or more of the subtypes of DTS.

Undiagnosed and untreated DTS co-conspirators can cause exacerbation of DTS and/or

misdiagnosis because of the underlying condition. Other diseases that affect the ocular surface and tear film, such as allergic conjunctivitis, frequently coexist in patients with DTS and contribute to the signs and symptoms. All identified DTS co-conspirators should be addressed as part of a patient's treatment regimen. Treatment of these other ocular conditions is outside the scope of this monograph and should be managed according to the clinician's preferred treatment options. The 'Diagnostics and clinical assessments' section presents further discussion and detailed information pertaining to the description and interpretation of the diagnostic tests that are used to obtain a differential diagnosis.

### Step 6: treatment options

Once a differential diagnosis has been attained, including identification of all subtypes of DTS and/or DTS co-conspirators that may be present, a directed treatment regimen should be implemented to address the patient's condition. Table 6 summarizes the treatment options recommended by the DTS Panel for the four main subtypes of DTS. First-line therapy, second-line therapy, and interventional procedures are presented for each subtype of DTS, as appropriate. Inflammation and a reduced quantity or quality of the tear film is central to the various subtypes of DTS. As such, some of the recommended treatment options are included for multiple categories.

Artificial tears, gels, ointments, and inserts are used to replenish the tear film. Tears can be conserved via punctal plugs, cautery, and moisture chamber eyewear. Alterations in environmental conditions may benefit patients with DTS through increases in relative humidity. Adjustments in lid hygiene, warm compresses, and massage may also be necessary for patients with blepharitis/MGD. Anti-inflammatory and immunomodulatory agent options include cyclosporine, lifitegrast, steroids, and nutritional supplements, such as omega-3 fatty acids. In addition to the conventional treatments for DTS, innovative treatment options, including compounded formulations of agents, are also available.

The overall severity of a patient's DTS is an important factor that affects the sequence and frequency of the treatment regimen. The particular sequence for first-line therapy, second-line therapy, and interventional procedures is a decision best left to the individual clinician according to the patient's medical history, prior treatment, and severity of the current disease state. The 'Treatment options for

dysfunctional tear syndrome' section presents a detailed discussion of each of the treatment options for the subtypes of DTS.

### Step 7: follow-up

Patient follow-up via regular clinic visits is an essential part of successful treatment of DTS. The fluctuations that occur in patient symptoms, signs, and diagnostic test results require the clinician to observe the patient over a period and to tailor treatment on the basis of response to therapy and changes from baseline values. Observed trends in inflammatory markers or tear film osmolarity provide a quantitative assessment of the progress of treatment from both the clinician and patient perspectives. The chronic nature of DTS and the frequent lack of correlation of clinical signs and patient symptoms emphasize the importance of monitoring a patient over time and making adjustments to the treatment plan, as necessary.

## DIAGNOSTICS AND CLINICAL ASSESSMENTS

A wide range of clinical assessments and diagnostic measures can be employed in the diagnosis of DTS. No single assessment or diagnostic procedure is sufficient for a differential diagnosis of DTS [6]. Identification of the specific subtypes of DTS is essential to determine a directed treatment approach. A thorough review of the patient's medical history, including past and current DTS symptoms and treatment, provides the context for interpretation of the current examination and diagnostic test results. This section presents the diagnostic tools that can be used to identify subtypes of DTS. Equipment access at each clinic and the preferences of each clinician differ and will influence the chosen diagnostic methods.

### Questionnaires

Patient-reported symptoms and the effects of DTS on daily activities can provide important information pertaining to the disease-state subtype and the severity of the condition. Although the clinically observed signs and patient-reported symptoms of DTS do not often correlate, addressing patient discomfort or functional limitations due to symptoms is a significant factor in determining the treatment approach. Validated questionnaire instruments designed with ranked scoring systems allow for quantification of patient responses and an overall estimate of the severity of their discomfort and the

## New Strategies for Diagnosis and Treatment of DTS

**Table 6.** Recommended treatment options for the DTS Panel clinical approach

Treatment option	Aqueous tear deficiency	Blepharitis/meibomian gland dysfunction (evaporative or nonevaporative)	Goblet cell deficiency/mucin deficiency	Exposure-related DTS
First line <sup>a</sup>	Tear supplements and lubricants (i.e., drops, gels, ointments, sprays, and lubricating inserts)	Tear supplements and lubricants (i.e., drops, gels, ointments, sprays, and lubricating inserts)	Tear supplements and lubricants (i.e., drops, gels, ointments, sprays, and lubricating inserts)	Tear supplements and lubricants (i.e., drops, gels, ointments, sprays, and lubricating inserts)
	Nutritional supplements	Lid hygiene and lid scrubs (i.e., cleansers, warm compresses, and massage)	Topical cyclosporine	Taping of the eyelid
	Topical cyclosporine	Nutritional supplements	Topical lifitegrast	Moisture chamber eyewear
	Topical lifitegrast	Topical cyclosporine	Vitamin A ointment – retinoic acid (compounded)	
	Topical steroids	Topical lifitegrast	Moisture chamber eyewear	
	Topical secretagogues	Topical erythromycin/bacitracin	Topical secretagogues	
	Moisture chamber eyewear	Topical azithromycin		
		Topical steroids or antibiotic/steroids		
Second line <sup>a</sup>	Oral secretagogues	Oral doxycycline/tetracycline	Scleral lenses	Scleral lenses
	Topical hormones (compounded)	Tea tree oil		
	Autologous serum (compounded)	Topical metronidazole ointment or drops (compounded)		
	Albumin (compounded)	Topical doxycycline (compounded)		
	Bandage contact lenses/scleral lenses	Topical clindamycin (compounded)		
	Topical dapsone (compounded)	Topical dehydroepiandrosterone (compounded)		
	Topical tacrolimus (compounded)	Topical dapsone (compounded)		
	Topical N-acetylcysteine	Topical N-acetylcysteine		
Procedures <sup>a</sup>	Punctal plugs	In-office thermal pulsation and/or lid massage		Eyelid surgery (i.e., correction of lid malposition and tarsorrhaphy)
	Cautery occlusion	Debridement of the lid margin		
	Amniotic membrane transplantation	Intense pulsed light		
		Meibomian gland probing		

Refer to the main text for the description, level of evidence, and approved indications, as appropriate. DTS, dysfunctional tear syndrome.

<sup>a</sup>The order of treatment in each category is left to the clinical judgment of the clinician and to the preference of the patient.

effect on visual function [4]. Patient responses to individual questions contribute to the overall score in the assessment and may also help direct the diagnosis of the particular DTS subtype.

A variety of questionnaires to evaluate the symptoms of dry eye have been developed [4]. Questionnaires such as the Ocular Surface Disease Index (OSDI) [54] and the Standard Patient Evaluation of Eye Dryness [55] are commonly used in standard

clinical practice to assess patient symptoms and in clinical trial research to screen potential individuals or to evaluate the effect of treatment on individual-reported symptoms and visual function [54].

### Slit-lamp examination

Detection of abnormalities affecting the eyelid, anterior and posterior lid margins, conjunctiva,




and cornea observed during the slit-lamp examination offers insight toward a differential diagnosis of DTS subtypes and identification of DTS co-conspirators that may exacerbate a patient's DTS condition [6]. During the initial portion of the slit-lamp examination, the following should be observed in detail:

- (1) Tear film meniscus (tear lake) and any debris or foam that may be present in the tear film
- (2) Lashes for any abnormalities (i.e., loss, misdirection, sleeves, scurf, and collarettes)
- (3) Anterior and posterior lid margins, noting the characterization of the vasculature and any abnormalities in the meibomian gland orifices
- (4) Nature of the meibomian gland secretions – grade 0–3 scale: 0 = clear/normal; 1 = cloudy; 2 = cloudy particulate fluid; and 3 = inspissated (like toothpaste) [5] (Fig. 3)
- (5) Appearance of the puncta
- (6) Any anomalies of the conjunctiva and cornea (i.e., hyperemia, mucus strands, scarring, and epithelial erosions) [5]

Each abnormality may be ranked as mild, moderate, severe, or according to some other system to allow for a baseline comparison at follow-up visits.

Once the initial examination is complete, dye is introduced on the ocular surface to further evaluate the tear film and corneal/conjunctival tissue. Instillation of liquid sodium fluorescein or application of fluorescein dye via moistened strips to the ocular




**FIGURE 3.** Meibomian gland orifices and expression of the meibomian glands. Image from a patient with posterior blepharitis/meibomian gland dysfunction (MGD). Obstruction of the orifices of the meibomian glands and alterations in the meibum, leading to turbid, thickened secretions, can occur in patients with blepharitis/MGD. © 1994 American Academy of Ophthalmology.

surface allows for visualization of the tear film and integrity of the corneal and conjunctival epithelium (Fig. 4). Fluorescein dye will penetrate tissue where the epithelial intracellular junctions have been disrupted (i.e., cells that are dead or absent). The stability of the tear film can be observed via the slit lamp with a cobalt blue filter following application of fluorescein. To evaluate the stability of the tear film, the TBUT test is usually conducted before any other drops or anesthetic are applied. The patient is instructed to blink a few times, and the time interval between blinking and disruption of the tear film is measured several times for each eye (averaging the time for each eye). A rapid TBUT (<10 s) is considered abnormal and often indicates evaporative tear disease/MGD and/or aqueous tear deficiency [6,19].

During evaluation of TBUT, the pattern of the tear film disruption may offer insight into the nature of the damage to the ocular surface tissue. In addition to the presence or absence of staining of the ocular surface, the severity and pattern of the staining may assist in the differential diagnosis of DTS or DTS co-conspirators. Evaluating patients across multiple visits with consistent application of the tests will allow for trends to be observed, which help overcome the fluctuation in clinical signs often observed in patients with DTS.

Table 7 presents corneal/conjunctival fluorescein staining patterns characteristically associated with a range of ocular conditions. Vital dyes, including lissamine green (Fig. 5) and rose bengal (rose



**FIGURE 4.** Corneal fluorescein staining. Image from a patient with aqueous deficiency. The disruption in the integrity of the corneal epithelium is highlighted by the application of fluorescein staining to the ocular surface. Moderate-to-severe staining with fluorescein is depicted in the photograph. Image courtesy of Karl Stonecipher, MD.


**Table 7.** DTS Panel approach ocular surface fluorescein staining patterns<sup>a,b</sup>

Severe	Moderate	Blepharitis	(right eye)	Contact lens-related	Superior limbic keratitis
<b>keratoconjunctivitis sicca</b>	<b>keratoconjunctivitis sicca</b>	<b>Exposure keratopathy</b>	<b>Medication toxicity</b>	<b>keratitis</b> (especially likely in a rigid gas permeable contact lens wearer)	<b>Foreign body under lid</b>
Severe blepharitis	Blepharitis	(thyroid eye disease, lagophthalmos, inferior lid	Keratoconjunctivitis sicca (less likely, but possible)	Keratoconjunctivitis sicca	Blepharitis
Chemical injury	Chemical injury (hairspray keratopathy)	lagophthalmos, scleral show, ectropion, partial or incomplete blink, and conjunctivochalasis)	Blepharitis	Blepharitis	Floppy lid syndrome
Severe medication toxicity	Ultraviolet exposure keratitis/arc welding keratitis	Keratoconjunctivitis sicca (less likely, but possible)	Entropion	Chemical injury (hairspray toxicity)	Conjunctival concretions
Contact lens-related keratitis due to hypoxia, solution toxicity (i.e., H <sub>2</sub> O <sub>2</sub> ), and cracked contact lens	Contact lens-related keratitis	Chemical injury	Trichiasis	Ultraviolet exposure keratitis/arc welding keratitis	Vernal keratoconjunctivitis
Infectious keratitis	Infectious keratitis	Entropion	Exposure keratopathy (thyroid eye disease, lagophthalmos, inferior lid lagophthalmos/scleral show, ectropion, and partial or incomplete blink)	Medication toxicity	Infectious keratitis
Neurotrophic keratitis	Thyroid eye disease/exposure keratopathy	Trichiasis		Infectious keratitis	Superior entropion
Ultraviolet exposure keratitis/arc welding keratitis	Neurotrophic keratitis	Medication toxicity		Exposure keratopathy (thyroid eye disease, trichiasis, pterygium, pinguecula, and band keratopathy)	Atopic keratoconjunctivitis
Trichiasis	Trichiasis	Infectious keratitis			Trichiasis
Filamentary keratitis					
Conjunctival concretions					

<sup>a</sup>Conditions listed in bold are considered more likely and/or high on the differential list.

<sup>b</sup>Characteristic corneal staining patterns indicative of particular conditions affecting the ocular surface may be observed following application of fluorescein dye.

bengal may be uncomfortable when applied to the ocular surface) (Fig. 6), are recommended to be applied to the ocular surface once the fluorescein evaluation is complete. Vital stains assist in the



**FIGURE 5.** Staining of the conjunctiva with lissamine green. Image from a patient with aqueous deficiency. Vital dyes, such as lissamine green, may be used to visualize debris in the tear film and regions of the conjunctiva that are deficient in mucin. Moderate-to-severe lissamine green staining of the temporal aspect of the conjunctiva is shown. Image courtesy of Elizabeth Yeu, MD.

visualization of debris in the tear film and areas of the ocular surface that do not have a mucus coating (i.e., cells that are ‘unhealthy or abnormal’) [20,21,56]. Table 8 presents corneal/conjunctival lissamine green/rose bengal staining patterns characteristically associated with a range of ocular



**FIGURE 6.** Staining of the conjunctiva with rose bengal. Image from a patient with aqueous deficiency. Rose bengal may be used to highlight areas of the conjunctiva that are abnormal or unhealthy in patients with dysfunctional tear syndrome (DTS). Moderate staining of the conjunctiva is shown with a classic pattern for keratoconjunctivitis sicca. © 1994 American Academy of Ophthalmology.

**Table 8.** DTS Panel approach ocular surface lissamine green/rose bengal staining patterns<sup>a,b</sup>

<p>Mild presentation of:</p> <p><b>Keratoconjunctivitis sicca</b> (classic pattern)</p> <p>Blepharitis</p> <p>Chemical injury (hairspray keratopathy)</p> <p>Ultraviolet exposure keratitis/arc welding keratitis</p> <p>Medication toxicity</p>	<p>Moderate presentation of:</p> <p><b>Keratoconjunctivitis sicca</b> (classic pattern)</p> <p>Blepharitis</p> <p>Chemical injury (hairspray keratopathy)</p> <p>Ultraviolet exposure keratitis/arc welding keratitis</p> <p>Medication toxicity</p>	<p>Severe presentation with filaments (noted in green) of:</p> <p><b>Keratoconjunctivitis sicca</b> (classic pattern)</p> <p>Blepharitis</p> <p>Chemical injury (hairspray keratopathy)</p> <p>Ultraviolet exposure keratitis/arc welding keratitis</p> <p>Medication toxicity</p>	<p><b>Mucus fishing syndrome</b></p> <p>Chemical injury</p> <p>Medication toxicity</p> <p>Inferior ectropion</p> <p>Entropion</p> <p>Trichiasis</p> <p>Conjunctivochalasis</p>	<p><b>Superior limbic keratoconjunctivitis</b></p> <p>Foreign body under lid</p> <p>Atopic keratoconjunctivitis</p> <p>Floppy lid syndrome</p> <p>Conjunctival concretions</p> <p>Vernal keratoconjunctivitis</p> <p>Infectious keratitis</p> <p>Superior entropion</p>

<sup>a</sup>Conditions listed in bold are considered more likely and/or high on the differential list.

<sup>b</sup>Characteristic conjunctival staining patterns indicative of particular conditions affecting the ocular surface may be observed following application of lissamine green or rose bengal dye.

conditions. It is important to note that mild fluorescein staining may be present even in normal eyes [6]. Also, diagnostic procedures, such as the Schirmer test, may result in mild staining with fluorescein, rose bengal, or lissamine green in the region where the test strip was placed.

Scoring systems for ocular surface staining have been developed in an effort to standardize patient assessments for clinical practice and research. Adoption of a scoring system is not necessary for use of the DTS Panel approach to arrive at an accurate diagnosis; however, clinicians may find the use of a scoring system (e.g., National Eye Institute scale or Oxford scheme) helpful in monitoring a patient’s response to treatment [30,57,58].


**Schirmer test**

The Schirmer test is a diagnostic method for evaluating aqueous tear production [19,59]. Clinicians use several variations of this procedure. Topical anesthesia may or may not be used during the procedure, and, in keeping with clinician preference, the procedure may include nasal stimulation to induce reflex tearing. The use of topical anesthesia prior to the assessment allows for the measurement of basal tear secretion, as compared with basal plus reflex tearing from the nonanesthetized version of the test. To perform the test, a narrow strip of filter paper (Schirmer strip) is placed in the inferior cul-de-sac near the lateral canthus (Fig. 7). Excess fluid in the fornix should be dried prior to insertion of the test strip. The

length of the test strip that is wetted after 5 min is measured in millimeters. A Schirmer test score of less than 10 mm after 5 min is generally considered abnormal [6,15].

The phenol red thread test is an alternative method to evaluate tear volume. The thread is placed in the inferior cul-de-sac toward the lateral canthus [3]. The length of the thread wetted (indicated by a color change) in 15 s is measured and recorded. A length of less than 10 mm of the thread after 15 s is considered abnormal.

Although the Schirmer test is frequently used in the diagnosis of various subtypes of dry eye, the



**FIGURE 7.** Schirmer strip test. Illustration of a patient undergoing Schirmer strip testing. Abnormalities in the production of the aqueous component of the tear film may be diagnosed using Schirmer strip testing. The Schirmer strip is placed in the inferior cul-de-sac near the lateral canthus.



results of the test are often variable [60]. Single abnormal test results may not be considered sufficient for a diagnosis. As with other diagnostic procedures used to assess patients with potential DTS, the observation of trends indicating consistently abnormal findings are beneficial in determining a differential diagnosis [6,15].

Members of the DTS Panel recommend the use of the Schirmer test as part of the battery of diagnostic assessments. Panel members use the test on both anesthetized and nonanesthetized patients. Both methods of employing the tests are correct and provide insight into the patient's aqueous tear production capacity. Additionally, a Schirmer test assessment should be considered for patients with DTS prior to punctal plug insertion to decrease the risk of secondary epiphora.

### Tear film osmolarity

Osmolarity is a measurement of the concentration of dissolved solutes in a solution. In terms of the tear film, osmolarity is generally expressed in units of milliosmoles per liter. Hyperosmolarity of the tear film is a recognized and validated marker of dry eye [13]. Hyperosmolarity of the tear film occurs through decreased flow of the bulk aqueous component of the tear film from the lacrimal gland and/or through increased evaporation and instability of the tear film. Increased osmolarity of the tear film stimulates the release of inflammatory cytokines, enhances the rate of cell apoptosis, and results in a decrease in the number of goblet cells [12,13].

Patients with a normal tear film typically have a stable tear film osmolarity. A higher degree of fluctuation in tear film osmolarity is observed in patients with DTS. Fluctuations occur both between measurements taken from the same eye and measurements concurrently taken between the eyes of a patient. The inherent fluctuations in tear film osmolarity of patients with DTS can be a point of confusion for clinicians unless the instability of the tear film is recognized as a hallmark of DED. A point-of-care test for the measurement of the osmolarity of the tear film of patients suspected of having DTS is available [14]. In general, an elevated tear film osmolarity correlates with DTS. The normal tear film osmolarity in patients without DTS ranges from 270 to 308 mOsm/l (mean of 302 mOsm/l). A threshold of 308 mOsm/l has been found to be indicative of early/mild dry eye, whereas a tear film osmolarity of 316 mOsm/l or higher is correlated with moderate-to-severe dry eye. Mean tear film osmolarity values of patients with mild-to-moderate dry eye are 315 mOsm/l, whereas those

of patients with severe dry eye have been found to be 336 mOsm/l. Based on the stability of the tear film in the eyes of normal patients, a difference in the tear film osmolarity of more than 8 mOsm/l between the eyes is suggestive of ocular surface instability and indicative of DED [12–14]. In addition to the specific tear osmolarity values associated with the severity of DED listed previously, clinicians may also find it useful to generally categorize the assessed severity level using ranges of up to 300 mOsm/l for normal, 300–320 mOsm/l for mild, 320–340 mOsm/l for moderate, and above 340 mOsm/l for severe DED [61].

Evaluation of tear film osmolarity should be conducted prior to disturbance of the eye to obtain accurate results because any disturbance to the ocular surface may stimulate reflex tearing, which can falsely lower the osmolarity reading [62]. Although an elevated measurement of tear film osmolarity is a strong indicator of DTS, the presence of an elevated osmolarity reading may not correlate with a patient's symptoms or other clinical signs [62] because of the nature of the disease and fluctuations observed in these patients. Trends observed through multiple osmolarity assessments are beneficial to increase the sensitivity and specificity of the diagnosis of individual patients. If used, tear film osmolarity should be assessed at the initial evaluation of a patient with DTS and at follow-up visits to establish a baseline and quantify the patient's response to treatment as the tear film stabilizes. The tear film osmolarity assessment has been demonstrated to have an 88% specificity and 78% sensitivity for mild/moderate dry eye and a 95% sensitivity for severe dry eye [6,13,14]. Despite these results, some studies question the accuracy of the tear film osmolarity assessment and have shown variability in the osmolarity measurements, with a lack of strong correlations with other signs and symptoms of DED [63–66]. Bunya *et al.* [63] suggest that tear film osmolarity testing has feasibility in the clinical setting and induces less discomfort than the Schirmer test. On the basis of their experience, members of the DTS Panel have found the assessment of tear osmolarity helpful for diagnosing DTS when used in combination with other clinical assessments and procedures.

### Inflammatory markers in the tear film

Inflammation is a common factor across the subtypes of DTS. The inflammatory cascade responsible for producing inflammation on the ocular surface in DTS offers the opportunity to correlate measurements of inflammatory biomarkers with



the severity of the disease. The levels of inflammatory mediators, including cytokines, chemokines, and enzymes, involved in tissue remodeling may be assessed in the tear film. Recent research has evaluated a member of the MMP family, MMP-9, an enzyme produced by corneal epithelial cells, as a biomarker for dry eye [16,17]. The MMP family of enzymes plays an important role in wound healing and inflammation through the ability to degrade collagen. Elevated levels of MMP-9 have been observed in the tears of patients with dry eye [67].

The normal range of MMP-9 in the tears of patients ranges from 3 to 40 ng/ml. In contrast, the MMP-9 levels in the tears of patients with moderate-to-severe DTS can exceed 40 ng/ml. A point-of-care test for the measurement of the concentration of MMP-9 in the tear film of patients suspected of DTS is available [18,67]. Because of a requirement for MMP-9 levels to be greater than 40 ng/ml to provide a positive assessment using the point-of-care diagnostic, the use of MMP-9 as a diagnostic measure may be valid only for patients with more severe forms of DTS [68].

### Corneal sensation

The cornea, one of the most highly innervated tissues in the body, is susceptible to alterations in sensitivity because of damage or injury. Irritation or injury to the ocular surface due to hyperosmolarity or inflammation triggers the reflex arc to stimulate the lacrimal gland secretions. Changes in the sensitivity of the cornea have been observed in patients with chronic conditions such as DTS. Sensitivity may be increased during the early stages of the disease, whereas a reduction in corneal sensitivity is associated with disease progression [19,69,70].

Instruments to precisely quantify corneal sensitivity, such as the Cochet–Bonnet esthesiometer, are available and used in basic research or clinical trial settings [71]. In general clinical practice, access to esthesiometers may be limited; consequently, qualitative methods can be employed to assess changes in a patient's corneal sensitivity. Basic scoring systems may be developed through the use of simple tests for sensation, in which a cotton swab, unwaxed dental floss, or the tip of a tissue is gently applied to the ocular surface. In the authors' clinical experience, grading scales, including numeric scales (0–4, ranging from no sensation to normal sensation exhibited via a reflex to pull away) or descriptive scales (normal, decreased, or none), may be used to characterize corneal sensation.

### Lacrimal gland secretion biomarkers


The secretions of the lacrimal gland that form the bulk of the aqueous component of the tear film contain a range of proteins, including enzymes and immunoglobulins, electrolytes, and other factors involved in maintaining the health of the ocular surface. Assessments of the protein components of lacrimal secretions have found altered levels in the tear film of patients with diseases affecting the ocular surface, which allows these proteins to be used as biomarkers [72,73].

Lactoferrin, a molecule belonging to the transferrin class of proteins, is one of the most abundant protein components of the healthy tear film. Through the sequestration of iron, lactoferrin acts as an antimicrobial agent and plays a role in the immunologic and anti-inflammatory properties of the tear film. The concentration and absolute protein levels of lactoferrin in the tear film have been observed to be reduced in patients with aqueous-deficient dry eye [74]. A point-of-care test for the measurement of the concentration of lactoferrin in the tear film of patients suspected of having DTS is available. Lactoferrin levels below 0.9 mg/ml suggest the patient has ADDE, with the severity of the disease correlating with lower levels of the biomarker [72,73].

The immunoglobulin family of proteins plays an essential role in the functioning of the immune system. IgE proteins, antibodies specific for particular allergens, are found in the tear film of patients with ocular allergic conditions. Exposure to allergen particles results in binding of IgE and interaction with mast cells in the conjunctiva, initiating the inflammatory response of the allergic cascade [75,76]. A commercially available point-of-care test designed to evaluate the level of IgE in tear samples with IgE levels at least 80 ng/ml suggests a diagnosis of allergic conjunctivitis, with the level of IgE present in the tear film correlating with the severity of the allergic condition [53].

### Optical coherence tomography

OCT is a noninvasive technique that uses light waves to construct a three-dimensional, high-resolution, cross-sectional image of biologic tissues or fluids. OCT devices capable of evaluating the anterior segment offer the opportunity to quantify aspects of the tear film. The precise height, volume, and cross-sectional area of the tear meniscus can be measured. Figure 8 presents a representative OCT image showing the cross-sectional area of a normal tear meniscus [77]. In addition to a comparison of the tear meniscus characteristics to the mean



**FIGURE 8.** Evaluation of the tear film meniscus with optical coherence tomography (OCT). Image of the cross-sectional area of the tear film meniscus with OCT. Evaluation of the tear film with a high-resolution OCT allows for the characteristics of the tear film to be quantified. The area of the inferior meniscus was calculated to be  $0.05 \text{ mm}^2$  in this patient, which was within the normal range [77]. Image courtesy of Elizabeth Yeu, MD.

values of patients with DTS versus those without DTS, OCT offers a means to monitor a patient's response to treatment options. Improvements in the tear meniscus following the installation of punctal plugs or other therapy for DTS allow the clinician to provide quantitative feedback to patients [78,79]. Recent advances include the automation of analysis of the tear meniscus height over multiple image scans, which potentially increase the accuracy of the measurement compared with a single scan [80].

### Interferometry and meibography

Interferometry is a noninvasive technique that can be used to measure the thickness of the tear film through the use of the principle of optical interference or the interaction of light waves. Colored images of the superficial layer of the tear film, the lipid layer, can be generated and evaluated to assess the thickness across the ocular surface [15,81].

Diagnostic devices are commercially available, allowing for the visualization and assessment of a patient's tear film lipids [82,83]. A reduction in the thickness of the lipid component of the tear film ( $<60 \text{ nm}$ ) has been correlated with MGD and symptoms of dry eye [78]. Diagnostic systems also allow for the recording of a patient's blink cycle, thereby determining whether a full closure of the interpalpebral fissure is occurring [78]. Upgrading the diagnostic systems allows for visualization of the meibomian gland via

meibography, further assisting in the differential diagnosis of MGD (Fig. 9). Meibography techniques may be used to visualize alterations in the meibomian glands, such as dropout, dilation, and truncation [83,84].


### Serologic biomarkers

Sjögren syndrome is a systemic autoimmune disease that often includes ADDE as an ocular manifestation. The salivary glands are affected in many patients, and symptoms of dry eye and dry mouth are considered hallmark indications of Sjögren syndrome. Serologic testing, confirming the presence of autoantibodies, including SS-A or SS-B, has been typically required to diagnose primary or secondary Sjögren syndrome. Novel antibodies that appear to be detectable early in the development of Sjögren syndrome have recently been identified [85]. A diagnostic panel that tests for autoantibodies to salivary protein-1, parotid secretory protein, and carbonic anhydrase VI, in addition to the traditional autoantibody markers for Sjögren syndrome, is available. The diagnostic panel uses a small blood sample from the patient, which is obtained by finger prick or venipuncture. The availability of this diagnostic panel, which contains early biomarkers for Sjögren syndrome, enables earlier detection and directed treatment of this progressive condition [85–87].

### TREATMENT OPTIONS FOR DYSFUNCTIONAL TEAR SYNDROME

A directed treatment plan based on a differential diagnosis is considered key to achieving the primary goal of the DTS Panel approach to improving patient outcomes. This section presents treatment options for the DTS clinical subtypes. Overlap of specific treatment options occurs between DTS subtypes, and, in such cases, the information presented reflects the published evidence or expert opinion supporting the use of a therapy for that particular condition.

Each section includes information pertaining to treatment options approved by the US Food and Drug Administration for a specific indication, as appropriate. This section also includes additional therapeutic options on the basis of a review of the published evidence and the expert opinion of the authors, in which evidence is limited. Information and recommendations considered 'off-label' are also included. As such, the decision and manner to use any therapy is best determined by each individual clinician's best judgment.



**FIGURE 9.** Visualization of the meibomian glands, tear film lipid layer, and partial blinking. Image of a patient with meibomian gland dysfunction (MGD) and exposure-related dysfunctional tear syndrome (DTS). Diagnostic systems designed for visualization of the meibomian gland (meibography) are also capable of providing an analysis of the thickness of the tear film lipid layer and an assessment of partial blinking. Note a decrease in lipid layer thickness of 46 nm in the right eye and 43 nm in the left eye; increased partial blinking OU; and meibomian gland truncation OD greater than OS. Image courtesy of Mark Milner, MD.

Multiple treatment options are presented for each subtype of DTS. Although the emphasis of this approach is to direct treatment on the basis of the specific disease-state subtype(s) for each patient, the relative severity of a patient's condition is also an important consideration in the sequence and/or combination of therapies applied in any treatment regimen.

Table 6 categorizes the treatment options in groups recommended for first-line therapy, second-line therapy, and interventional procedures. It is important to keep in mind, however, that each patient is unique, and the decision regarding which treatment option(s) to use is best left to the individual clinician. Treatment options for each DTS subtype are presented on the basis of treatment category rather than the order in Table 6.

Patient education regarding early diagnosis, risk factors, treatment options, and prognosis of DTS is considered a part of the first-line treatment plan for all subtypes of DTS. All patients may benefit from efforts to mitigate the severity

and effect of DTS symptoms on quality of life through potential adjustments to their behavior, daily activities, and exposure to environmental stressors.

### Aqueous deficiency treatment options

#### Tear supplements and lubricants

Tear supplements and topical lubricants are available in a range of options for the treatment of ocular symptoms associated with DTS. Artificial tears serve to lubricate the ocular surface and remove debris, supplement-deficient components of the tear film, dilute a hyperosmolar tear film, and reduce elevated levels of proinflammatory mediators [4,5,88–91]. The current array of tear supplements and lubricants are distinguished by their formulation differences, which include variations in viscosity, electrolytes, pH, osmolarity, and the presence/type of a preservative [4].

Artificial tears are considered as first-line therapy for tear deficiency and other types of DTS because of



availability, their noninvasive nature, and a generally minimal side-effect profile [6]. Clinical studies investigating the efficacy of various formulations of tear supplements have been conducted, including comparative studies to evaluate the differential effects on patient symptoms and clinical signs of DTS [92]. The use of preserved tear supplements is appropriate for many patients with mild tear deficiency to relieve the symptoms of DTS, as needed. However, because of the potential for disruption of the tear film and toxicity to the corneal epithelium, the authors recommend that patients with moderate-to-severe tear deficiency requiring the use of artificial tears more than four times per day use preservative-free formulations. The potential for ocular toxicity has been well characterized for benzalkonium chloride. Newer preservative agents may still potentially damage the corneal epithelium [92–95]. Preservative-free artificial tear supplements may be used liberally, as needed.

### **Lubricating inserts**

Hydroxypropyl cellulose ophthalmic inserts are sterile, water soluble, and slow-release lubricants that are placed in the inferior cul-de-sac. Hydroxypropyl cellulose ophthalmic inserts are indicated for patients with moderate-to-severe dry eye. Because the formulation is preservative free, it may help patients who are not able or willing to use artificial tears on a frequent basis [96,97]. Published clinical evidence of efficacy (level II) has reported a significant improvement in tear deficiency symptoms and OSDI scores with once-daily use of hydroxypropyl cellulose ophthalmic inserts [98,99]. Transient blurred vision was the most common adverse event reported that was associated with use of the hydroxypropyl cellulose ophthalmic inserts [97,98].

### **Nutritional supplements**

Essential fatty acids, including omega-3 and omega-6 fatty acids, must be obtained through dietary consumption. Omega-3 and omega-6 fatty acids are required for the normal function of human cellular metabolism. Dietary intake of essential fatty acids may play a role in the risk for developing subtypes of DTS. A diet that has a higher ratio of omega-6 fatty acids (a precursor for proinflammatory mediators) is associated with an increased risk of dry eye. Conversely, a diet that has a high ratio of omega-3 fatty acids is associated with a reduced chance of developing dry eye [100].

Evidence from clinical investigations involving dietary supplements, primarily omega-3 fatty acids, generally supports that intake is associated with an improvement in the symptoms of tear

deficiency. Recent meta-analyses of randomized, placebo-controlled studies (level I) indicated that significant improvements in TBUT and Schirmer test scores were associated with daily dietary intake of omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) [101]. Significant improvements in individual-reported symptoms (OSDI assessment) and objective evaluations of corneal smoothness were observed in a clinical evaluation of long-term consumption (6 months) of nutritional supplements containing gamma-linolenic acid and omega-3 fatty acids by patients with moderate-to-severe dry eye compared with ingestion of a placebo (level I). The study reported that no ocular adverse events were attributed to the nutritional supplement or to the placebo; similarly, no significant systemic adverse events were noted in either treatment group [102]. Omega-3 fatty acid supplements are available from a range of sources and formulations [101]. Clinical investigation regarding the recommended dosage and formulation of these supplements is ongoing.

### **Topical cyclosporine**

Inflammation associated with the ocular surface and secretory components of the lacrimal system is believed to be a core feature of the pathogenesis of dry eye. Changes in the functioning of the lacrimal gland and/or lacrimal ducts may affect both the quantity and quality of the secretions of the lacrimal gland that form the bulk aqueous component of the tear film [103,104]. Inflammation associated with the ocular surface may be induced through chronic irritation due to environmental stress, ocular comorbidities, physiologic changes associated with aging, or ocular manifestations of systemic conditions. Therapy with anti-inflammatory agents is recommended because of the strong correlation of inflammation with tear deficiency [4,6,105,106].

Cyclosporine A, a peptide derived from a fungal origin, is an anti-inflammatory agent with immunosuppressive properties. Topical application of cyclosporine (0.05%) to the ocular surface is indicated to increase tear production in patients who have decreased tear production due to inflammation associated with dry eye [107]. The precise mechanism of action of topically applied cyclosporine is unknown; however, the agent is believed to act as a T-cell immunomodulator in patients with tear deficiency [107].

Phase 3 clinical studies supporting the approval of topical cyclosporine for the treatment of dry eye indicated a significant increase in Schirmer test scores in individuals treated with cyclosporine twice daily compared with those treated with



vehicle (level I). A significant decrease in fluorescein corneal staining and improvement in subjective measures (e.g., blurred vision, need for artificial tear use, and global response to treatment) were also observed in the individuals treated with topical cyclosporine compared with those treated with vehicle [4,107,108]. An early response time ranging from 4 to 6 weeks to 3 months may be observed in patients, and benefits may continue to improve for 2 years or more. Clinical improvements in the signs and symptoms of DED were observed in patients with severe manifestations of the disease following high-frequency administration (three to four times daily) of topical cyclosporine (level II) [109]. Ocular burning and stinging were the most commonly reported adverse events in the individuals treated with topical cyclosporine [108–110]. The authors recommend a dosage regimen of twice-daily application of topical cyclosporine to both eyes in the treatment of tear deficiency for a minimum of 6 months [111]. Patients should be assessed at follow-up visits, and therapy is commonly maintained indefinitely for this chronic condition, as appropriate. According to the judgment of the clinician, if the patient's signs and symptoms have fully resolved, therapy with topical cyclosporine may be discontinued or reduced to once-daily administration following 1 year of twice-daily treatment. Clinical evidence indicates that once-daily administration following 1 year of twice-daily administration may still suppress the signs and symptoms of DED (level II) [112]. Members of the DTS Panel have used topical cyclosporine therapy for 2 years or more for patients with aqueous deficiency. Limited safety information is available from the published studies evaluating long-term and/or a reduced administration regimen of topical cyclosporine.

### Topical lifitegrast

Activation and recruitment of immune cells, specifically lymphocytes, occur in the development and perpetuation of DTS through the binding of receptors on the surface of immune cells with molecules expressed on the epithelium of the ocular surface and vascular endothelium. Lymphocyte function-associated antigen-1 (LFA-1) is a member of the integrin receptor family that is expressed on lymphocytes and binds to adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-1). Inhibition of the interaction between LFA-1 and ICAM-1 by the integrin receptor antagonist lifitegrast (SAR 1118) results in blocking the recruitment, activation, and release of proinflammatory mediators by lymphocytes [113–115].

Topical application of a lifitegrast ophthalmic solution (5.0%) is indicated for the treatment of the signs and symptoms of DED [116]. Clinical evaluation of topical lifitegrast in the treatment of individuals with dry eye (twice-daily administration) resulted in significant improvement in corneal and conjunctival staining as well as improvements in ocular symptoms, including eye dryness, compared with placebo [115,117,118]. Adverse events were generally mild to moderate and transient in nature, with the majority of ocular adverse events related to instillation in both treatment groups (e.g., reduced visual acuity, irritation, and discomfort), whereas dysgeusia was the most common nonocular adverse event reported by individuals treated with lifitegrast [115,118,119].

The approved dosage regimen of topical lifitegrast is twice-daily application to both eyes (OU) [116]. Patient response to treatment should be assessed at follow-up visits, and therapy may be maintained indefinitely, as appropriate.

### Topical secretagogues

Secretagogues are agents that induce secretion as a mechanism of action. Application of secretagogues to the ocular surface are designed to stimulate aqueous and/or mucin secretion. Topical therapeutic agents in the secretagogue class have been investigated, but are not currently available in the United States [120,121]. Topical secretagogue formulations (e.g., 3% diquafosol sodium ophthalmic solution and 2% rebamipide ophthalmic suspension) are available internationally and indicated for the treatment of dry eye [122,123].

### Topical steroids

Corticosteroids are anti-inflammatory compounds with use in treating a range of ocular inflammatory conditions. In the United States, topical ophthalmic formulations of corticosteroids are generally indicated for the treatment of steroid-responsive inflammatory conditions affecting the anterior segment. Clinical evidence from multiple studies using different formulations indicates that corticosteroids are effective in reducing the inflammatory aspects of DTS. Statistically significant reductions in the signs (conjunctival hyperemia) and symptoms of individuals diagnosed with keratoconjunctivitis sicca were observed in groups treated with corticosteroids (loteprednol etabonate ophthalmic suspension, 0.5%) compared with those treated with placebo (level I) [105]. Statistically significant improvements were also observed in individuals with keratoconjunctivitis sicca (associated with Sjögren syndrome) who were treated with corticosteroids

(nonpreserved methylprednisolone), followed by the insertion of punctal plugs after 2 weeks, with regard to clinical signs (corneal fluorescein staining) and ocular symptoms, compared with individuals receiving punctal plug insertion alone (level I) [124]. Corticosteroid treatment of individuals with keratoconjunctivitis sicca, with and without Sjögren syndrome, resulted in significantly greater improvements in ocular symptoms and signs (fluorescein and rose bengal staining) compared with treatment with artificial tears alone or nonsteroidal anti-inflammatory drops (flurbiprofen) along with artificial tears (level I) [125].

Members of the DTS Panel have used a dosage regimen for topical corticosteroids of one to four times per day (OU) for 2–4 weeks for the treatment of tear deficiency, as appropriate, according to the severity of the condition. Although all ophthalmic corticosteroid formulations are considered suitable for the treatment of inflammation associated with tear deficiency, clinicians are advised to consider formulations that may decrease the risk of steroid-associated adverse effects (e.g., fluorometholone, loteprednol etabonate, and low-concentration [0.01%], preservative-free dexamethasone), such as elevated intraocular pressure (IOP) and cataract formation, for patients considered at risk for such a response [105,126–128].

### Moisture chamber eyewear

Environmental factors, such as low humidity, drafts, and windy conditions, can exacerbate the symptoms of tear deficiency. Conversely, increases in periocular humidity have been reported to increase the thickness of the tear film lipid layer and lengthen the interblink time interval. The use of eyeglasses with side shields or goggles offers a non-invasive option to reduce environmental desiccating stress while increasing periocular humidity. Patients may directly purchase wrap-around glasses or specialty goggles [6,129,130].

### Punctal plugs and cautery occlusion

Enhanced retention of tears on the ocular surface can be achieved by blocking the pathway for tear clearance and drainage. Increasing retention of the tear film on the ocular surface offers a complementary strategy to enhance aqueous production via other therapeutic options. Punctal occlusion can be achieved through the insertion of plugs or thermal cautery. Different types of punctal plugs may be used to offer temporary blockage of tear film drainage, such as with absorbable collagen and polymer plugs, or placed for an indefinite time frame through the use of nonabsorbable silicone or

thermal labile polymer plugs. Permanent punctal occlusion in the form of thermal or laser cautery may be performed on patients. Before permanently occluding the puncta, a trial period with silicone punctal plugs can be beneficial to evaluate the risk of epiphora [4,131].

Multiple studies have demonstrated the clinical efficacy of punctal occlusion in the reduction of the clinical signs and symptoms of tear deficiency (level II). Improvement in the symptoms of DTS was observed in the majority of patients in these studies (74–86%). Clinical improvements related to the signs of DTS were observed, including corneal staining, TBUT, and tear film osmolarity. Adverse effects related to punctal occlusion include epiphora, foreign body sensation, ocular irritation, infection, pyogenic granuloma, and loss of the inserted plugs (internally and externally) [132–134]. Treatment for ocular surface inflammation prior to the insertion of punctal plugs is recommended [4].

### Autologous serum

Naturally occurring biologic fluids, such as serum, offer a lubricant that mimics the composition of natural tears in many ways and may be used as a tear supplement. The use of autologous serum ameliorates the risk of antigenicity. Serum contains many of the components present in the tear film, including immunoglobulins, enzymes, and growth factors [135,136]. Data supporting the clinical efficacy of autologous serum in randomized, well controlled studies are limited; however, clinical investigation in individuals with dry eye and Sjögren syndrome (level II/level III) reported improvement in patient symptoms, TBUT, and corneal and conjunctival staining. No complications were reported following instillation of autologous serum [137].

Preparing and maintaining the sterility of preservative-free autologous serum can be a limiting challenge in the use of this therapy. If available, a 20–50% preparation, diluted in artificial tears, may be used as a therapeutic option and applied four to eight times a day (OU) [135,137]. In areas in which autologous serum is not available or desired, other biologic fluids, including preparations of allogeneic serum [138], umbilical serum [139], and platelet lysate [140], may be used in the treatment of patients with severe forms of DED.

### Albumin

Serum albumin is a major component of human serum and is commercially available in a purified form. As an alternative to direct preparation of serum eye drops, compounded formulations of

serum albumin have been investigated in the laboratory and clinic for the treatment of dry eye. Animal models of corneal erosions using 5 or 10% serum albumin indicated a positive improvement in corneal healing and rescue of corneal epithelial cells [141,142]. Clinical evaluation of a 5% serum albumin formulation was conducted via a case series (level III) in the treatment of patients with Sjögren syndrome. Significant improvements in ocular surface staining were observed in patients following treatment with 5% albumin every 4 h after 4 weeks of treatment. No adverse events were reported with serum albumin instillation [141].

### Topical hormones

Steroid hormones are potent signaling molecules, with regulatory effects on many physiologic processes when applied systemically. Hormone replacement therapy, particularly estrogen alone, has been associated with an increased risk of dry eye in epidemiologic studies of postmenopausal women [143]. However, the effect is unclear because evidence of a benefit to patient symptoms with hormone replacement therapy has also been reported [144]. During the aging process, both men and women generally experience a decrease in the production of androgens and women experience a decrease in the production of estrogen [145]. The presence of receptors for sex hormones on the lacrimal and meibomian glands suggests a regulatory role in the function of these glands, with a potential effect on DTS [146–148].

Although data from clinical investigations into the efficacy of topical hormone therapy for the treatment of tear deficiency are currently limited, the reported evidence encourages further investigation. A case study review [149] and anecdotal reports (level III) from clinicians indicate that the use of topical hormone therapy may be beneficial in the treatment of the ocular signs and symptoms of patients with a deficient tear film. Topical application of medroxyprogesterone has been used in the treatment of alkali burns and is associated with a reduction in corneal perforation, ulceration, and healing of persistent corneal epithelial defects (level II) [150].

Patients with tear deficiency have been treated with compounded formulations of medroxyprogesterone acetate, 1%; progesterone, 0.5%/testosterone, 0.5%; and dehydroepiandrosterone (DHEA), 0.5 or 1.0%, all of which may be prepared at compounding pharmacies, with treatment instilled two to six times per day (OU). No ocular adverse events have been reported with the use of topical hormone therapy for DTS. The safety and efficacy of

compounded hormone ophthalmic preparations have not been fully investigated, and investigational uses are left to the judgment of each clinician.

### Topical dapsone

Dapsone, or diaminodiphenyl sulfone, is available for oral administration as a systemic antimicrobial agent for the treatment of skin conditions (e.g., dermatitis herpetiformis) or acne vulgaris as a topical agent (5% gel) [151,152]. Although dapsone is considered an anti-infective, anti-inflammatory/immunosuppressive properties have also been recognized. Dapsone has also been used systemically in the treatment of ocular mucous membrane pemphigoid [153].

The clinical evidence pertaining to the safety and efficacy of topical dapsone for the treatment of ocular inflammatory conditions such as DTS is limited to case studies and anecdotal reports (level III). Compounded dapsone (0.25%) has been used for the treatment of patients with tear deficiency as an innovative approach to address the ocular inflammation associated with this condition. A dosage regimen of four times a day for 2 weeks followed by twice-daily administration for an indefinite period has been reported to be effective in the treatment of tear deficiency. No ocular complications or adverse events have been reported with the use of topical dapsone in the treatment of DTS [154]. The safety and efficacy of compounded dapsone for ocular use has not been fully evaluated, and investigational use is to be determined by the judgment of each clinician.

### Tacrolimus

Tacrolimus is a compound belonging to the macrolide class of antibiotics that also exerts anti-inflammatory immunosuppressive effects. Tacrolimus ointment is indicated for dermatologic use (e.g., atopic dermatitis). The 0.03 and 0.1% formulations are commercially available, and other concentrations can be obtained from a compounding pharmacy [155]. Similar to cyclosporine, tacrolimus functions as a calcineurin inhibitor. Anti-inflammatory and immunosuppressive activity has been reported through inhibition of lymphocyte activation and the release of inflammatory mediators, including interleukin-4, interleukin-8, and tumor necrosis factor- $\alpha$  [156].

Limited data regarding the direct use of topical tacrolimus for the treatment of DTS are available. The results of the use of topical tacrolimus (0.03%) for the treatment of a case series (level III) of patients with Sjögren syndrome indicate that a significant improvement in the clinical signs of tear deficiency (fluorescein and rose bengal staining as well as

TBUT and Schirmer test scores) was observed following twice-daily treatment with a compounded formulation. Mild ocular discomfort was reported following instillation of the topical tacrolimus formulation [157]. The safety and efficacy of tacrolimus for ocular use has not been fully evaluated, and investigational use is to be determined by the judgment of each clinician.

### **Bandage contact lenses and scleral contact lenses**

Soft contact lenses have become widely adopted for use in alleviating discomfort and improving epithelial healing associated with ocular surgical procedures, such as refractive surgery [158]. Clinical studies have investigated the use of bandage contact lenses in the treatment of dry eye and other ocular conditions associated with aqueous deficiency. Symptomatic relief and a reduction of the expression of inflammatory markers in the tear film (MMPs) were observed in association with the use of bandage contact lenses to promote corneal epithelial healing (level II) [159]. Significant improvements in best-corrected visual acuity, corneal staining, and ocular symptoms were observed in patients with severe dry eye due to Sjögren syndrome who used bandage contact lenses (level II) [160]. Bandage contact lenses are also recommended as a treatment option for the management of ocular conditions associated with aqueous deficiency, such as filamentary keratitis [161]. Potential safety concerns associated with the use of bandage contact lenses include infection, edema, ocular irritation/discomfort, and reduced visual acuity [159–161].

Scleral contact lenses are specialty devices that are fitted to rest on the conjunctiva and sclera rather than on the cornea. The lens material is generally rigid in nature and constructed to be gas permeable, with the capacity to hold a reservoir of fluid under the lens, thereby hydrating and protecting the cornea from exposure and abrasion [162,163].

Scleral contact lenses are often reserved for use by patients with moderate-to-severe tear deficiency. The lengthy process required to design a custom-fitted lens and the associated expense may deter the widespread use of scleral lenses as a treatment option for tear deficiency [164]; however, improvements in patient comfort, enhanced visual acuity, and healing of persistent corneal epithelial defects have been reported. Complications and adverse events associated with reports of clinical benefit of scleral contact lenses include corneal neovascularization, which is likely associated with the patient's initial ocular condition [164–166].

### **Oral secretagogues**

Oral secretagogues are pharmaceutical agents designed to stimulate secretion by target tissues via systemic administration. Cholinergic agents, such as pilocarpine and cevimeline, are available for oral administration for the treatment of dry mouth. Pilocarpine and cevimeline activate muscarinic acetylcholine receptors in the salivary and lacrimal glands to stimulate secretion. Clinical evaluation indicates that the main benefit of oral secretagogue therapy in patients with Sjögren syndrome is relieving the symptoms of dry mouth, although improvements in ocular symptoms have been observed [167]. Improvements in blurred vision and a reduction in ocular symptoms associated with reading were also observed in patients treated with oral secretagogues. Adverse effects related to the oral administration of cholinergic agents frequently include excessive sweating and gastrointestinal upset [167–169]. Members of the DTS Panel recommend referral to a primary care physician or rheumatologist for dosing and monitoring.

### **Topical N-acetylcysteine**

N-Acetylcysteine (NAC) is a derivative of L-cysteine, a naturally occurring amino acid. NAC has been widely used as a systemic therapeutic agent for systemic conditions and as a topical agent to treat filamentary keratitis and corneal thinning and melts as a result of the compound's mucolytic, antioxidant, anti-inflammatory, and anticollagenolytic properties [170,171].

Topical formulations of NAC (5%) have been investigated for the treatment of dry eye. Statistically significant improvements were observed in the symptoms reported by patients with dry eye who were treated with topical NAC four times a day for 2 weeks compared with those who were treated with only artificial tears (level II). No significant differences regarding the changes in the clinical signs of dry eye were observed in the two treatment groups. Incidents of ocular burning upon instillation were reported with administration of topical NAC [172].

### **Amniotic membrane transplantation**

Transplantation of the amniotic membrane (AMT), the thin inner layer of the placenta, is a recognized therapeutic option to facilitate healing of the ocular surface during treatment of severe ocular conditions. Preserved amniotic tissue may be inserted onto the ocular surface to function as a temporary graft to aid in the healing of persistent epithelial defects, acute chemical burns, or conjunctival scarring [173,174]. Amniotic membrane transplantation



may be beneficial in the treatment of complications of DTS, including keratitis, recurrent corneal erosions, recurrent pterygium, and corneal neovascularization, and of those of DTS co-conspirators [175]. Commercially available preparations of amniotic membrane are available for use as a corneal bandage and are indicated for the treatment of conditions in which the ocular surface tissue is damaged, inflamed, or scarred. Adverse events associated with AMT transplantation have been reported to include residual epithelial defects, spontaneous extrusion of the implant, eye pain, and headache [175,176]. Recent advances in tissue preservation and availability may allow for a larger-scale investigation pertaining to the clinical use of AMT for the treatment of patients with tear deficiency [4,6,177].

### **Additional surgical procedures**

In addition to the procedures mentioned previously in this section, surgical techniques to correct eyelid malposition, including limited tarsorrhaphy, may be used in the treatment of patients with severe tear deficiency. The 'Exposure-related dysfunctional tear syndrome' subsection presents an additional discussion of these procedures.

### **Blepharitis/meibomian gland dysfunction (evaporative and nonevaporative) treatment options**

#### **Tear supplements and lubricants**

The use of tear supplements and lubricants are recommended as first-line therapy for patients with blepharitis/MGD [5,7]. Formulations of artificial tears with higher viscosity, in addition to gel and ointment options, are generally considered to have an enhanced residence time on the ocular surface. Tear supplements, emulsion drops, and sprays designed to enhance the lipid component of the tear film are also available and have been evaluated in patients with evaporative tear disease associated with posterior blepharitis/MGD. Reports indicate improvements in individual symptoms, ocular surface staining, TBUT, expressibility of the meibomian glands, and lipid layer thickness (levels I–III) [178–182].

In addition to supplementation of the lipid component of the tear film, artificial tears and lubricants are used in patients with blepharitis/MGD to reduce tear film osmolarity, rehydrate the ocular surface, and assist in the removal of debris or irritants [4,5,89–91]. As discussed in the 'Aqueous deficiency treatment options' section, because of concerns regarding the effects of preservatives on the ocular surface [92], the authors recommend a nonpreserved formulation for patients using

artificial tear supplements in excess of four times per day [92–95].

#### **Eyelid hygiene/application of heat/massage**

Eyelid hygiene, in combination with applied heat and massage of the lids, is often the mainstay of treatment for the different types of blepharitis and MGD. Methods for lid cleansing, heat delivery, and manipulation of the lids can vary from in-office procedures to practices easily performed in a patient's home setting [5,7]. The nature and frequency of the specific form of therapy that is recommended is based on the subtype of blepharitis/MGD present. In general, lid hygiene is emphasized for the treatment of anterior blepharitis, whereas warm compresses and massage are recommended for posterior blepharitis/MGD [5,7,183].

Cleansing and care of the eyelid and lid margin are particularly important in patients with anterior blepharitis. Crusting, debris, scurf, and scales can be removed through a combination of lid cleansers (e.g., commercially available products or a nonirritating soap/shampoo) applied using a pad, wipe, cotton applicator, or fingertip and moist heat for several minutes. Cleansing of the eyelids and lid margin may be necessary on a daily basis or several times a week, depending on the severity of the patient's condition [7]. In cases in which a patient fails to respond to general lid hygiene procedures, antibiotics are usually necessary (as noted subsequently). Where an infestation with *Demodex* is suspected, application of diluted tea tree oil (50%) via lid scrubs to the lid margin may be beneficial in reducing the signs and symptoms of blepharitis. Tea tree oil and lid scrubs may be used alone or in conjunction with a nonirritating shampoo diluted in warm water for cleansing the lid margin [7,184]. Cleaning and debridement of the lid margin may also be conducted as an in-office procedure.

Warm compresses, with or without moisture, may be applied using simple home techniques, including hot towelettes, gel packs, or mechanical methods, to apply heat during an in-office procedure. Application of heat to the eyelids allows for expression and clearance of altered meibomian gland secretions, which are often associated with MGD. Gentle massage of the eyelids in conjunction with heat application facilitates expression of the meibomian glands. Multiple clinical studies have reported evidence of the clinical benefit for patients with MGD via improvement of the signs and symptoms associated with the condition [82,185–187]; however, there is a wide variation among studies in the techniques used and the method of application of warm compresses and lid massage. Automated,

in-office procedures providing heat, with massage (thermal pulsation) or without massage, may be conducted using commercially available devices [82,185–187]. Improvements in ocular signs and symptoms were observed to persist for up to 6 months following a single in-office treatment with automated application of heat and lid massage [82,185].

Alternatives to conventional lid hygiene and warm compresses/massage include meibomian gland probing and intense pulsed light therapy. Meibomian gland intraductal probing is conducted as an in-office procedure to offer symptomatic relief using a microcannula to open meibomian gland orifices in patients with obstructive MGD (level III) [188]. Intense pulsed light therapy involves the use of commercial devices during an in-office procedure to deliver high-intensity visible light therapy. Intense pulsed light is generally used to treat dermatologic conditions. Early clinical investigations into the use of the technique for patients with MGD indicate that the procedure may be beneficial in the treatment of signs and symptoms, including lid erythema and telangiectasia, with dermatologic adverse effects reported in 13% or less of individuals (level III) [189–191].

### Nutritional supplements

Essential fatty acids obtained through dietary consumption, such as omega-3 and omega-6 fatty acids, appear to be involved in the regulation of inflammation associated with posterior blepharitis/MGD. The relative proinflammatory nature of omega-6 fatty acids versus the anti-inflammatory properties of omega-3 fatty acids has led to investigation of the role of these essential nutrients in evaporative forms of DTS. Current treatment guideline recommendations include nutritional supplements containing omega-3 fatty acids as a treatment option for patients with blepharitis/MGD [5,7].

Improvements in the clinical signs and symptoms of DED have been reported in individuals taking daily omega-3 fatty acid supplements, as discussed in the 'Aqueous deficiency treatment options' section [101]. Clinical studies specifically investigating the use of omega-3 fatty acid dietary supplements in the treatment of blepharitis and MGD have also been conducted (level I/II). Significant improvements in symptom scores, TBUT, meibum expression, contrast sensitivity, and inflammation of the lid margin were observed in individuals receiving omega-3 fatty acid supplements [192–194]. Clinical investigation regarding the recommended dosage and formulation of omega-3 fatty acid supplements is ongoing.

### Topical cyclosporine

Chronic inflammation is a component of blepharitis/MGD. As such, the use of topical cyclosporine as a treatment option for these conditions as well as for aqueous deficiency has been investigated. Several small clinical studies (level II) investigating the application of topical cyclosporine in the treatment of MGD have been conducted. Significant improvements were observed in patient-reported symptoms, TBUT, ocular surface staining, telangiectasia, and lid margin vascular injection in individuals treated with topical cyclosporine compared with those treated with only control/placebo (artificial tears) [195,196] or tobramycin/dexamethasone (0.3%/0.1%) [197]. Improvements in the clinical signs of MGD were generally apparent following treatment with topical cyclosporine for 2 months or longer. Ocular burning, discomfort, and/or drug intolerance were reported following instillation of topical cyclosporine for the treatment of blepharitis/MGD [195,196]. The safety and efficacy of the use of topical cyclosporine for the treatment of blepharitis/MGD is still being investigated, and investigational use is best determined by the judgment of each clinician.

### Topical lifitegrast

The integrin receptor antagonist lifitegrast is an immunomodulatory agent that blocks the recruitment, activation, and release of proinflammatory mediators by lymphocytes [113–115]. Chronic inflammation and EDE are frequently associated with MGD, the most common form of DED [5,25]. Topical application of a lifitegrast ophthalmic solution (5.0%) has been evaluated for the treatment of patients with DED, and is indicated for treatment of the signs and symptoms of DED [116]. At this time, the safety and efficacy of the use of topical lifitegrast has not been evaluated for the treatment of patients with MGD; however, lifitegrast may be used in the treatment of the signs and symptoms of DED that may be present in patients with MGD. Specific effects on the meibomian glands are not known.

Topical lifitegrast should be applied twice-daily to both eyes (OU), as indicated [116]. Patient response to treatment should be assessed at follow-up visits, and therapy may be maintained indefinitely, as appropriate.

### Topical antibiotic ointment

Infectious blepharitis, one of the subtypes of anterior blepharitis, frequently involves colonization and overgrowth of microorganisms, including *Staphylococcus aureus*, coagulase-negative staphylococcal

species, such as *Staphylococcus epidermidis*, and *Propionium acnes* [33,198]. Topical commercially available ointment formulations of erythromycin, bacitracin, or other antibiotic agents are recommended for the treatment of anterior blepharitis. Topical antibiotic formulations are generally recommended for use at bedtime or twice daily for 3 weeks in the treatment of anterior blepharitis [7]. Recurrences of anterior blepharitis are common; as such, periodic treatment with topical antibiotic ointments may be needed.

The precise role of pathogenic bacteria or overgrowth of normal flora in the cause of posterior blepharitis/MGD is less clear. Bacteria may often be cultured from the lid margin of patients with posterior blepharitis/MGD, and bacterial toxins may play a role in the pathogenesis of the condition and destabilization of the tear film through saponification of the lipids expressed by the meibomian glands. Irritation and inflammation from the production of inflammatory mediators is believed to contribute to the chronic nature of posterior blepharitis/MGD [199,200].

### **Azithromycin**

Azithromycin is an antibiotic agent belonging to the macrolide class of therapeutic agents. Topical azithromycin (1%) is indicated for the treatment of bacterial conjunctivitis. Azithromycin has an expanded spectrum of activity and a pharmacokinetic profile that results in high tissue concentrations and an extended elimination half-life. Anti-inflammatory properties, which are distinct from the direct antibiotic effects, have been observed for azithromycin. The anti-inflammatory properties of azithromycin include inhibition of immune cell migration and the activation of nuclear factor kappa B and expression of proinflammatory cytokines and chemokines [201,202].

Clinical studies have investigated the use of oral and topical formulations of azithromycin for the treatment of anterior and posterior blepharitis/MGD. Improvements in the signs (e.g., TBUT, conjunctival redness, and ocular surface staining) and symptoms (e.g., ocular itching, eyelid itching, and ocular dryness) of meibomitis and posterior blepharitis/MGD have been observed in individuals treated with oral azithromycin, generally using pulse therapy, over the course of 1 month (level II) [203–205]. Statistically significant improvements have also been observed in patient-reported symptoms, meibomian gland plugging, quality of meibomian gland secretions, TBUT, and ocular surface staining of individuals with mixed anterior and posterior blepharitis (level II) [206,207] as well as of those with posterior blepharitis/MGD

alone (level II) [208–211] who were treated with topical azithromycin. These preliminary studies reported that topical instillation of azithromycin was generally well tolerated. Additionally, spectroscopic studies indicated improvements in the phase transition temperature and lipid order structure of the meibomian gland secretions of patients treated with topical azithromycin [210]. A twice-daily dosage regimen (OU) for 2 days followed by daily administration (for 2–4 weeks of therapy) of topical azithromycin has been generally used in the preliminary investigation of the treatment of blepharitis/MGD. A pulsed regimen of topical azithromycin may also be used as needed because of its high ocular tissue distribution and prolonged elimination half-life [211]. Gastrointestinal adverse events were reported with oral administration of azithromycin [204,205]. Ocular adverse events associated with topical administration of azithromycin include eye pain, ocular irritation, and blurred vision [207,209,211]. The clinical safety and efficacy of azithromycin for the treatment of blepharitis/MGD is still under investigation, and investigational use is best determined by the judgment of each clinician.

### **Topical steroid and steroid/antibiotic combinations**

Topical corticosteroid formulations, including drops or ointments, are a potent treatment option for the inflammation associated with the various subtypes of blepharitis and MGD. Combination steroid formulations that include an antibiotic may be used in the treatment of ocular inflammatory conditions, in which an infectious component is known or suspected to be part of the cause. Steroid/antibiotic formulations containing tobramycin have been evaluated for the treatment of manifestations of blepharitis (level II). Improvements in the clinical signs and symptoms (composite score) of blepharokeratoconjunctivitis were observed in individuals treated with both loteprednol etabonate/tobramycin (0.5%/0.3%) and dexamethasone/tobramycin (0.1%/0.3%) [212]. Because of potential serious adverse effects associated with topical ophthalmic steroid use, including elevated IOP and cataractogenesis, steroid formulations for blepharitis/MGD may be best reserved for control of inflammatory flare-ups and for the treatment of acute inflammatory/infectious conditions such as blepharokeratoconjunctivitis and marginal keratitis [5,7].

The authors recommend application of steroid ointment or steroid-antibiotic combination formulations to the lid or ocular surface one to four times per day for 2–4 weeks, as appropriate, according to



the severity of the condition. Clinicians are advised to consider formulations that may decrease the risk of steroid-associated adverse effects [e.g., fluorometholone, loteprednol etabonate, and low-dosage dexamethasone (0.01%)] in the treatment of DED and blepharitis/MGD [105,126–128,213].

### Topical metronidazole

Metronidazole is an antimicrobial agent in the nitroimidazole family that may be administered orally to treat systemic conditions or topically as a gel or ointment for dermatologic treatment of rosacea [214]. Metronidazole formulations have also been investigated for the treatment of ocular manifestations of rosacea and blepharitis associated with demodicosis. Clinical investigation of the treatment of patients with ocular rosacea with topical metronidazole (compounded topical formulation of 0.75%) in conjunction with lid hygiene was more effective than lid hygiene alone at improving overall eyelid scores and ocular surface signs (level II). No adverse events or complications were reported with topical application of metronidazole [214]. Clinical evidence pertaining to the efficacy of the treatment of blepharitis associated with *Demodex* infestation via case studies and a prospective study indicates that topical metronidazole in conjunction with lid hygiene or additional agents, such as ivermectin, is efficacious in reducing the counts of mites in the lash follicles and clinical signs of blepharitis, including lid margin thickening/erythema, and telangiectasia (level II/III) [215,216].

Formulations of metronidazole gel/ointment are available commercially (1–2%) and via compounding pharmacies at concentrations ranging from 0.375 to 2%. Commercially available preparations may be specifically labeled as ‘not for ophthalmic use’. DTS Panel members have used compounded metronidazole ophthalmic formulations, ointments (0.375–0.75%), and drops (0.5%) applied to the lid margin at bedtime or more frequently according to the severity of the patient’s blepharitis for 4 weeks to 6 months (or longer), as necessary. The clinical safety and efficacy of topical metronidazole has not been fully evaluated for the treatment of ocular rosacea/blepharitis, and investigational use is best determined by the judgment of each clinician.

### Tetracycline class agents

Tetracycline belongs to a class of antimicrobial agents, including the tetracycline derivatives doxycycline and minocycline, which are bacteriostatic agents with anti-inflammatory properties. Tetracycline agents have an established history for the treatment of dermatologic conditions, including

acne rosacea. Use of tetracycline class agents for the treatment of blepharitis and MGD has focused primarily on their anti-inflammatory properties, along with their additional effects on bacterial products that affect the tear film rather than direct antimicrobial effects [217–219].

Tetracycline agents suppress the production of staphylococcal lipase at concentrations below the threshold required for antimicrobial activity. Bacterial lipases produce free fatty acids and diglycerides with the potential to disrupt the tear film lipids and cause ocular irritation (level I/II) [220–222]. Additional anti-inflammatory and antiangiogenic properties have been observed in basic and clinical research, indicating that tetracyclines affect a range of inflammatory mediators, including MMPs and cytokines/chemokines (level I/II) [223,224].

Clinical investigations of the oral administration of tetracycline agents for the treatment of blepharitis/MGD have indicated a significant improvement of individual-reported symptoms and ocular inflammation/irritation [5,225]. The oral dosage of tetracyclines ranges from 20 mg/day by mouth for minocycline and doxycycline to 250 mg/day by mouth for up to four times a day for tetracycline, with no general consensus regarding the standardized dosage for the treatment of blepharitis/MGD [5]. Adverse effects that have been observed in patients receiving systemic tetracycline therapy include photosensitization, nausea, and headache [5,225,226].

In an effort to provide directed treatment for ocular conditions, potentially reducing adverse effects that occur frequently in patients undergoing systemic tetracycline therapy, topical doxycycline ophthalmic formulations may be obtained from compounding pharmacies. The authors have used a 0.025–0.1% formulation of doxycycline ophthalmic solution twice daily for the treatment of chronic forms of blepharitis/MGD. Ophthalmic ointment formulations of tetracycline compounds may also be used (at bedtime), if preferred. The safety and efficacy of the use of topical compounded tetracycline class agents for the treatment of blepharitis/MGD have not been evaluated, and investigational use is best determined by the judgment of each clinician.

### Topical clindamycin

Clindamycin is an antimicrobial agent in the lincosamide class of antibiotics. Clindamycin is effective against bacterial organisms, such as *S. aureus*, *S. epidermidis*, and *P. acnes*, and is generally used to treat systemic infections. Clindamycin may also be used to treat dermatologic conditions, such as rosacea and acne; however, very limited clinical



information is available regarding the use of topical clindamycin formulations for the treatment of ocular rosacea [227,228]. Anecdotally, members of the DTS Panel have reported improvement in the signs and symptoms of patients with ocular rosacea/posterior blepharitis following treatment with compounded topical clindamycin ointment (1%) at bedtime for durations of 6 months or longer, depending on the severity of the condition. The authors did not report any ocular adverse events or complications with the topical administration of clindamycin. The safety and efficacy of the use of topical compounded clindamycin for the treatment of ocular rosacea/posterior blepharitis has not been evaluated, and investigational use is best determined by the judgment of each clinician.

### **Topical dapson**

Dapsone is an antimicrobial agent with anti-inflammatory and immunosuppressive properties. Dapsone is available in topical formulations for the treatment of acne vulgaris [151,152]. As discussed in the 'Aqueous deficiency treatment options' section, available evidence supporting the use of topical dapson for DTS is limited to case studies and anecdotal reports (level III) [154]; however, the use of topical dapson is similar in nature to that of other antimicrobial agents with anti-inflammatory/immunosuppressive properties, such as macrolides, tetracycline agents, and metronidazole. Compounded dapson (0.25%) has been used for the treatment of patients with blepharitis/MGD to address the ocular inflammation associated with this condition. A DTS Panel member has used a treatment regimen of four times a day for 2 weeks followed by twice-daily administration for an indefinite period [154]. The safety and efficacy of compounded dapson for ocular use has not been evaluated, and investigational use is to be determined by the judgment of each clinician.

### **Topical dehydroepiandrosterone**

Changes in hormone levels associated with aging or autoimmune disease are associated with an increased risk factor for DTS. A decrease in the production of androgens generally occurs in both men and women during the aging process [142]. Basic research indicates that androgens are involved in stimulating the process of lipidogenesis in the meibomian glands [229].

Currently, no level I or level II studies have been conducted to evaluate the efficacy of topical androgen therapy for the treatment of blepharitis/MGD. Clinical evidence from a case study review [149] and anecdotal reports (level III) from clinicians indicate that the use of topical DHEA therapy may be

beneficial in the treatment of the ocular signs and symptoms of patients with posterior blepharitis/MGD. Patients with posterior blepharitis/MGD have used formulations of DHEA, 0.5 or 1.0%, which can be obtained from compounding pharmacies, with treatment instilled two to six times per day (OU). No ocular adverse events or complications have been reported with the use of topical hormone therapy for DTS. The safety and efficacy of compounded hormone ophthalmic preparations have not been investigated, and investigational uses are left to the judgment of each clinician.

### **Topical N-acetylcysteine**

In addition to the clinical evidence presented in the 'Aqueous deficiency treatment options' section, the efficacy of NAC in the treatment of MGD has also been evaluated. A small clinical study was conducted to assess the efficacy of topical NAC (5%) in conjunction with lid hygiene compared with preservative-free artificial tears and lid hygiene in patients with MGD (level II). Statistically significant improvements in TBUT and Schirmer scores were observed in the NAC treatment group compared with the artificial tear group following 1 month of therapy (four times a day). Significant improvements in patient-reported symptoms were observed in both groups compared with baseline [230]. A small follow-up study was conducted in patients with MGD to compare the efficacy of topical NAC with a topical combination steroid-antibiotic [betamethasone/sulfacetamide sodium (0.1%/10%)]. Statistically significant improvements in patient signs and symptoms were observed in both treatment groups after 1 month of therapy, and topical NAC appeared to be as effective as the topical steroid-antibiotic treatment. Topical NAC is reported to be well tolerated in the treatment of MGD [231].

### **Goblet cell deficiency/mucin deficiency treatment options**

#### **Tear supplements and lubricants**

The mucin component of the tear film is distributed across the inner glycocalyx, composed of polysaccharides attached to the surface of the corneal and conjunctival epithelium and soluble mucins that provide a gel-like consistency to the aqueous component of the tear film. Goblet cells present in the conjunctival epithelium secrete the majority of soluble mucin (MUC5AC) in the tear film. Goblet cell loss, with an associated reduction in tear mucins, is a contributing factor to DTS [232–234].

Artificial tears are the first-line therapy for patients with goblet cell deficiency/mucin deficiency

[6]. The use of tear supplements can provide relief of symptoms associated with DTS, lubrication of the ocular surface, and hydration of the patient's tear film. The range of tear supplement options for the treatment of ocular symptoms of DTS provides clinicians an array of choices for selecting the best fit for a particular patient's profile and needs. Patients with goblet cell loss may benefit from tear supplements with enhanced viscosity agents and a balanced electrolyte composition [232,235].

As presented in the 'Aqueous deficiency treatment options' section, clinical studies investigating the efficacy of various formulations of tear supplements have been conducted [92]. The authors recommend that patients with goblet cell loss and/or mucin deficiency use preservative-free formulations to avoid further damage to the conjunctival epithelium, particularly if tear supplements are used more than four times per day [92–95].

### Topical cyclosporine

Normal composition of the tear film requires a sufficient number of mucin-producing goblet cells in the conjunctiva. A reduction in the number of goblet cells in patients with dry eye has been correlated with reduced soluble mucin levels in the tear film. The density of goblet cells in the conjunctiva may be evaluated through samples collected by impression cytology [236].

In addition to the clinical evidence obtained during conduct of the topical cyclosporine, 0.05%, phase 3 registration studies indicating a significant increase in Schirmer test scores, significant increases in the density of goblet cells in the conjunctiva of patients treated with topical cyclosporine compared with those treated with vehicle were observed (level I). Goblet cell densities increased by approximately 191% in samples from individuals treated with topical cyclosporine [44,108]. An additional clinical investigation evaluated the increase in conjunctival goblet cell density in individuals treated sequentially with artificial tears followed by topical cyclosporine versus artificial tears alone. After 6 weeks of topical cyclosporine therapy, goblet cell density increases of 4.1-fold and 3.1-fold were observed in the temporal and inferior bulbar conjunctiva, respectively, of individuals in the cyclosporine group [236]. The members of the DTS Panel recommend a dosage regimen of twice-daily application of topical cyclosporine to both eyes (OU) in the treatment of goblet cell deficiency for a period of at least 6 months. Ocular burning and stinging were the most commonly reported adverse events in the individuals treated with topical cyclosporine [108]. As described in the 'Aqueous deficiency treatment options' section, patients

should be assessed at follow-up visits and therapy may be maintained indefinitely, as appropriate.

### Topical lifitegrast

A reduction in goblet cell density and mucin deficiency in the tear film is associated with both the aqueous-deficient and evaporative forms of DED [40–42]. The effect of topical lifitegrast treatment on goblet cell density and mucin production has not been evaluated; however, lifitegrast ophthalmic solution (5.0%) has been evaluated for the treatment of patients with DED, and is indicated for treatment of the signs and symptoms of DED [116]. Lifitegrast may be used in the treatment of the signs and symptoms of DED that may be present in patients with goblet cell loss and/or mucin deficiency.

The administration of topical lifitegrast for the treatment of the signs and symptoms of DED associated with goblet cell deficiency and/or mucin deficiency is twice-daily application to both eyes (OU), as indicated [116]. Follow-up visits should be conducted to assess the patient response to treatment, and therapy may be maintained indefinitely, as appropriate.

### Topical secretagogues

Topical secretagogue agents available internationally (diquafosol and rebamipide) induce mucin secretion as a component of the mechanism of action. Topical therapeutic agents have been investigated in the United States, but are currently not available [120,121]. Rebamipide has been demonstrated to increase the production of mucin from conjunctival goblet cells and corneal epithelial cells [237]. Diquafosol activates the purinergic P2Y2 receptor on conjunctival cells, and an increased release of MUC5AC from goblet cells was observed following topical application of diquafosol in canine research studies [238]. Topical secretagogue formulations (diquafosol sodium ophthalmic solution, 3%, and rebamipide ophthalmic suspension, 2%) are available internationally and indicated for the treatment of dry eye [122,123].

### Vitamin A ointment

Vitamin A (retinoids) is involved in multiple levels of cellular physiology and differentiation. Sufficient levels of vitamin A are essential for the development and maintenance of goblet cell levels in the conjunctiva [35,239]. Deficiency of vitamin A is an established risk factor for the development of dry eye, impacting the mucin component of the tear film as well as the acinar cells of the lacrimal system [6,240].

Treatment of patients who have an established deficiency of vitamin A with high oral doses is effective in replenishing goblet cells in the conjunctiva and improving healing of the corneal injury and damage (level II) [240]. Evidence for the clinical efficacy of a commercially available topical vitamin A drop formulation in the treatment of dry eye has also been observed in a study comparing treatment of patients with dry eye with topical cyclosporine, 0.05% (twice a day) or topical retinyl palmitate, 0.05% (four times a day). Significant improvements in conjunctival goblet cell densities were observed over 3 months in samples from both treatment groups compared with individuals instilling preservative-free artificial tears alone (level I). The most common ocular adverse events reported with instillation of topical vitamin A were ocular burning and stinging [241]. Vitamin A ointment can be compounded for topical ophthalmic use (all-trans-retinoic acid, 0.01%). Members of the DTS Panel have used vitamin A ointment for the treatment of patients with goblet cell deficiency at bedtime for 2–6 months according to the severity of the condition. The safety and efficacy of compounded vitamin A ointment for ocular use has not been evaluated, and investigational use is to be determined by the judgment of each clinician.

### **Moisture chamber eyewear**

Eyeglasses or goggles that provide a relative increase in periocular humidity are a noninvasive method for patients to reduce the symptoms associated with a rapid TBUT, similar to treatment for aqueous tear deficiency. Educating patients to avoid drafts and windy conditions by controlling environmental factors may help reduce the severity of patient discomfort. Patients may purchase eyeglasses with side shields or specialty goggles [6,129,130].

### **Scleral contact lenses**

As with patients with aqueous deficiency, scleral contact lenses designed to rest on the conjunctiva and sclera may be used to protect and maintain hydration of the cornea [162,163]. Scleral contact lenses may be a suitable treatment option for patients with moderate-to-severe goblet cell deficiency, compensating for a rapid TBUT. Custom-fitted scleral lenses offer a potential benefit to patients with evaporative tear disease and those with irregular astigmatism or complex refractive issues. Scleral contact lenses have been demonstrated to offer improvements in patient comfort, enhanced visual acuity, and healing of persistent corneal epithelial defects [164–166].

## **Exposure-related treatment options**

### **Tear supplements and lubricating agents**

Tear supplements and/or topical lubricant gel formulations are recommended as a first-line therapy for patients with exposure-related DTS [6]. Excessive drying of the ocular surface due to exposure may occur during the waking period or at night, depending on the underlying condition. The main tear film components (mucin, lacrimal gland secretions, and lipids) may be produced in sufficient quantity in patients with exposure keratopathy; incomplete blinking or malposition of the lids, however, may extend the duration of the interblink interval beyond the stability of the tear film. Artificial tears, tear film supplements, and lubricating gels may be used to hydrate the ocular surface and to reduce elevated levels of proinflammatory mediators that may be present as a result of extended exposure (level II/III) [4,5,88–91].

Artificial tears and tear supplements with higher viscosity and gel or ointment options may be used throughout the day, as needed, or at bedtime to hydrate and protect the ocular surface from extended exposure at night due to conditions such as nocturnal lagophthalmos. Tear supplements and lubricants may be used by patients with mild-to-severe exposure keratopathy to alleviate symptoms; however, the underlying condition should be addressed to avoid long-term damage to ocular surface tissue [1]. As previously discussed, the DTS Panel recommends that patients using artificial tears or supplements more than four times per day use a nonpreserved formulation because of potential toxicity issues with the corneal epithelium [92–95].

### **Taping of the eyelid**

Patients with nocturnal lagophthalmos and other conditions leading to exposure keratopathy may benefit from taping of the eyelid on the affected eye (at bedtime). Ointment, gel, or another ocular lubricant can be applied to the ocular surface or inferior fornix, and then a pad is taped into position over the closed eye, ensuring adequate closure of the lids [242].

### **Moisture chamber eyewear**

Eyeglasses, goggles, or other fabricated systems that increase the relative periocular humidity are noninvasive methods for patients to reduce the symptoms associated with exposure keratopathy. In conjunction with patient education regarding the avoidance of drafts and windy conditions, use of moisture chamber eyewear may help reduce the severity of patient discomfort. Patients may directly

purchase eyeglasses with side shields or specialty goggles for daytime use. Patients with nocturnal lagophthalmos may purchase sleep masks or specialty goggles for nighttime use. Systems that increase the periocular and ambient humidity may be beneficial for patients with exposure-related DTS [6,129,130,242].

### Scleral contact lenses

Patients with moderate-to-severe exposure-related DTS may benefit from the use of scleral contact lenses. Lenses that are designed to rest on the conjunctiva and sclera may be used to protect and maintain hydration of the cornea, providing protection to the ocular surface tissue from extended exposure due to lid malposition or another anatomic defect [162,163]. Scleral contact lenses have been demonstrated to offer enhanced patient comfort and visual acuity and healing of persistent corneal epithelial defects [164–166].

### Surgical procedures

Surgical options should be considered for the treatment of exposure keratopathy according to the underlying cause and severity of the condition. Referral of patients with anatomic disorders or significant lid or lash malposition (i.e., entropion, ectropion, trichiasis, or distichiasis) to an oculoplastic specialist may be necessary [1,4]. Restricting the size of the interpalpebral fissure through tarsorrhaphy may also be considered for patients with severe exposure keratopathy. Marginal, limited, or complete tarsorrhaphy procedures are therapeutic options, depending on the severity of the condition and response to prior therapy [1,4,242,243].

## EMERGING THERAPIES

Investigation into the pathophysiology, improved diagnostic techniques, and treatment options for DTS is an ongoing and active field of research. In addition to the treatment options listed for each DTS subtype, novel therapeutic agents are currently being advanced through late-stage clinical development.

### Topical cyclosporine

Novel formulations of topical cyclosporine for the treatment of dry eye have been proposed and investigated in the United States and internationally. Ocular formulations that have been investigated include concentrations of 0.1% cyclosporine as well as novel vehicle formulations of topical cyclosporine [244].

### Secretagogues

Rebamipide is a quinolone compound that was initially developed for the treatment of gastric ulcers. Rebamipide induces mucus secretion and has been shown to exhibit anti-inflammatory and cytoprotective properties in addition to improving wound healing. Investigation into the ocular properties of rebamipide to induce mucus secretion and induce epithelial healing as part of the treatment of dry eye has led to the approval and marketing of the compound in Japan. Clinical investigation into the safety and efficacy of rebamipide for the treatment of dry eye in the United States is ongoing [237].

Tavilermide (MIM-D3) is a peptidomimetic, a compound designed to resemble a short chain of amino acids, that is capable of stimulating mucus secretion and is also a partial agonist of the tropomyosin receptor kinase A receptor. Tavilermide functions as a peptidomimetic of nerve growth factor, a naturally occurring protein that plays a role in the survival and differentiation of neurons [245]. Early clinical evaluation of tavilermide in individuals with dry eye indicated significant improvements in signs and symptoms compared with placebo. Clinical investigation into the safety and efficacy of tavilermide for the treatment of dry eye is ongoing [245].

### Lacrimal neurostimulation

Stimulation of the neural circuits involved in control of basal and reflex tear secretion is being investigated through the use of a device designed to stimulate the nasolacrimal reflex. Improvements in the clinical signs and symptoms of patients with mild-to-severe DED were observed following administration of low-level neurostimulation to the sensory nerves in the nasal cavity [246,247]. Clinical investigation into the safety and efficacy of lacrimal neurostimulation for the treatment of dry eye is ongoing [248].

## CASE ILLUSTRATIONS

The following are example cases of how to apply the DTS Panel approach. These case studies are not meant to imply that there is only one way to handle patients with DTS, but to demonstrate the concept of applying a directed treatment approach following determination of a differential diagnosis. Optimal treatment is determined by individual assessment of each patient and his or her needs and wants (e.g., allergies and cost); by the clinician's experiences (i.e., 'the art of medicine'); and by the options available to each clinician.



**Case 1**

A 66-year-old woman complains of having burning, gritty, and irritated eyes for 1 year, with fluctuation of vision, especially when reading and using the computer.

**Past medical history**

- (1) Hypertension
- (2) Seasonal allergies (no ocular involvement reported at the time of the assessment)

**Past ocular history**

- (1) Contact lens wearer from age 17 to age 51
- (2) LASIK (laser-assisted in situ keratomileusis) OU at age 51 for distance OU

**Systemic medications**

- (1) Losartan
- (2) Fexofenadine as necessary

**Ocular medications**

- (1) Artificial tears OU five to six times daily

**Social history**

- (1) Smoker

**Examination**

- (1) Visual acuity: 20/20 OU without correction (sc); distance
- (2) Schirmer test scores: 2 mm OD and 3 mm OS after 5 min without anesthesia
- (3) Tear osmolarity (if available): 332 mOsm/l OD; 324 mOsm/l OS
- (4) Lids: 2+ (moderate) MGD with 'toothpaste-like secretions'; 2 mm of lagophthalmos OU
- (5) Conjunctiva: moderate rose bengal staining consistent with keratoconjunctivitis sicca; no conjunctival scarring
- (6) Cornea: no fluorescein staining
- (7) TBUT: 7 s OD; 8 s OS

**Diagnosis**

This patient has DTS secondary to:

- (1) Aqueous deficiency with a low Schirmer test score and rose bengal staining consistent with keratoconjunctivitis sicca
- (2) Evaporative dry eye without conjunctival scarring, with rapid TBUT OU
- (3) Blepharitis (posterior with MGD)
- (4) Exposure-related DTS with lagophthalmos

No DTS co-conspirators were noted, except for seasonal allergies.

**Treatment**

- (1) Topical anti-inflammatory/immunomodulatory [cyclosporine (0.05%) or lifitegrast (5.0%)] OU twice daily
- (2) Topical erythromycin (0.5%) ointment OU at bedtime
  - (a) Macrolides have both antibiotic and anti-inflammatory effects
  - (b) Azithromycin can also be used, but in this case, the advantage of the ointment will be seen with the lagophthalmos at bedtime
- (3) Warm compresses OU twice daily (beneficial for MGD)
- (4) Artificial tears (preservative-free) OU every 2 h as needed
- (5) Follow-up in 4–6 weeks

**Course**

Patient presents in 5 weeks stating that she is '50% better'. She has less burning and fluctuation of vision but still experiences symptoms of DTS.

**Examination**

- (1) Visual acuity: 20/20 OU sc; distance
- (2) Schirmer test scores: 5 mm OD and 5 mm OS after 5 min without anesthesia
- (3) Tear osmolarity (if available): 316 mOsm/l OD; 313 mOsm/l OS
- (4) Lids: 1+ (mild) MGD with fewer 'toothpaste-like secretions'; 2 mm of lagophthalmos OU
- (5) Conjunctiva: mild rose bengal staining consistent with keratoconjunctivitis sicca; OD > OS, but better
- (6) Cornea: no fluorescein staining
- (7) TBUT: 7 s OD; 8 s OS

**Assessment**

This patient has improved overall, with less severe MGD, improved rose bengal staining, and improved tear osmolarity, but still has signs and symptoms of DTS.

**Treatment**

- (1) Continue topical cyclosporine or lifitegrast OU twice daily
- (2) Consider changing erythromycin OU at bedtime to a reduced frequency of administration, such as OU at bedtime for the first 2 weeks of every month
- (3) Consider placing punctal plugs OU, lower lids. Schirmer test scores are still decreased. The level of healthy tears can be increased through the use of plugs now that the ocular surface

inflammation has been addressed through the use of cyclosporine or lifitegrast. If inflammation is still present, topical steroids can be included as part of the treatment regimen. Some may also choose to only continue with the current regimen because definite improvement has been noted. Topical anti-inflammatory/immunomodulatory agents may continue to allow further improvement with prolonged use, and further intervention may not be needed

- (4) Follow-up in 4–6 weeks

If the patient has no symptoms of DTS and no corneal staining at the follow-up visit, continue all medications and follow-up in 6 months. If she still has symptoms and/or staining, initiate another treatment option. For example, if the Schirmer test score is still low, add upper plugs. If Schirmer test scores are better, but MGD persists, add doxycycline by mouth or change from the erythromycin ointment to a topical metronidazole ointment OU at bedtime (compounded, 0.75%). Remember, an ‘additional treatment option’ may be giving the currently prescribed therapy more time to take effect. The lagophthalmos can be managed with moisture chamber eyewear and taping the lids closed at night. If the lagophthalmos continues to contribute to DTS, a referral to an oculoplastic surgeon may be necessary because of the severity of the condition and the patient’s response to treatment.

### Case 2

A 33-year-old man was referred by an internist for ocular evaluation of dry eyes after ‘pink eye’.

### Past medical history

- (1) Seasonal allergies
- (2) Asthma

### Past ocular history

- (1) Viral conjunctivitis (EKC) 2 months prior with pseudomembranes
- (2) Further history taking; patient ‘digs out mucus’ with his fingernails

### Examination

- (1) Visual acuity: 20/20 OD; 20/20 OS; best corrected (cc)
- (2) Schirmer test score: 24 mm OD and 30 mm OS after 5 min without anesthesia
- (3) Lids: normal
- (4) Conjunctiva: lissamine green staining consistent with mucus fishing syndrome (inferior

fornix); tarsal conjunctival scarring OU; superior mild papillary conjunctivitis secondary to possible atopic conjunctivitis (history of asthma)

- (5) Cornea: clear with no fluorescein staining
- (6) TBUT: 3 s OD; 4 s OS
- (7) MMP-9 testing (if available) positive for dry eye in both eyes

### Diagnosis

This patient has DTS secondary to:

- (1) Evaporative dry eye with conjunctival scarring  
Presumed goblet cell loss with mucin deficiency after EKC with pseudomembranes (and possibly from atopic conjunctivitis)

The DTS co-conspirators are mucus fishing syndrome and possible atopic conjunctivitis.

### Treatment

- (1) Topical cyclosporine (0.05%) OU twice daily may help with treating (a) inflammation (MMP-9 positive); (b) DED secondary to presumed goblet cell loss, based on conjunctival scarring and lack of MGD; and (c) atopic conjunctivitis
- (2) Artificial tears OU as needed (nonpreserved recommended if used more than four times per day)
- (3) Instruct the patient to discontinue mucus fishing and not to wipe his eyes while they are open
- (4) Consider starting a mast cell stabilizer/antihistamine and/or topical steroid depending on the severity of the allergic/atopic component
- (5) Follow-up in 4–6 weeks; may need to have the patient return within 4 weeks to monitor IOP according to the patient’s glaucoma risk if a topical steroid is prescribed

### Course

Patient presents in 4 weeks stating he is ‘60% better’ with respect to symptoms of DTS.

### Examination

- (1) Visual acuity: 20/20 OD; 20/20 OS; cc, distance
- (2) Lids: normal OU
- (3) Conjunctiva: no lissamine green staining OU
- (4) Cornea: no fluorescein staining OU
- (5) TBUT: 7 s OD; 5 s OS

### Treatment

- (1) Continue topical cyclosporine (0.05%) OU twice daily
- (2) Consider topical lifitegrast (5.0%) therapy (substitution or additional therapy), depending on the patient’s response to treatment

- (3) Add vitamin A ointment (compounded; all-trans-retinoic acid 0.01%) OU at bedtime; although the patient is better, he still has symptoms and a rapid TBUT that is presumed secondary to goblet cell loss
- (4) Follow-up in 4–6 weeks
- (5) Consider moist chamber goggles and environmental treatments, such as a humidifier
- (6) If topical steroid drops were included in the treatment regimen at the previous visit, taper over 1–2 weeks

If the patient has no symptoms and no corneal staining at the next follow-up visit, continue all medications and follow-up in 6 months. Alternatively, consider giving the currently prescribed therapy more time to take effect.

### Case 3

A 62-year-old woman is referred by an optometrist for dry eye that has not improved with artificial tears and collagen plugs. She complains of chronic irritation and a foreign body sensation.

#### Past medical history

- (1) Hyperthyroidism

#### Past ocular history

- (1) Dry eye
- (2) Blepharitis

#### Examination

- (1) Visual acuity: 20/40 OD; 20/40 OS; sc
- (2) Manifest refraction (MR): OD  $-0.50 -0.50 \times 175$  20/25; OS  $-0.50 -0.25 \times 04$  20/25
- (3) Schirmer test score: 22 mm OD and 18 mm OS after 5 min without anesthesia
- (4) Lids: 2+ (moderate) MGD with 2+ (moderate) erythema of the lid margins
- (5) Conjunctiva: superior injection OU; rose bengal staining superiorly OU with redundant conjunctiva superiorly OU; no evidence of lagophthalmos
- (6) Cornea: no fluorescein staining; no evidence of lagophthalmos
- (7) TBUT: >10 s OD; >10 s OS
- (8) Tear osmolarity (if available): 280 mOsm/l OD; 295 mOsm/l OS

#### Diagnosis

- (1) Posterior blepharitis
- (2) MGD with evidence of an abnormal tear film demonstrated by the >8 mOsm/l difference in the tear osmolarity between the eyes, despite both eyes being in the normal range

The DTS co-conspirator is SLK.

#### Treatment

- (1) Topical azithromycin (1.0%) OU at bedtime (helps with MGD)
- (2) Warm compresses OU twice daily
- (3) Loteprednol etabonate gel (0.5%) OU twice daily for 2 weeks (helps with SLK and MGD)
- (4) Follow-up in 4 weeks

#### Course

At a follow-up of 4 weeks, the patient complained of minimal improvement in DTS symptoms.

#### Examination

- (1) Visual acuity: no change in visual acuity with MR
- (2) Lids: improvement in blepharitis and MGD
- (3) Conjunctiva: persistent superior injection and superior rose bengal staining
- (4) Cornea: no corneal staining

#### Treatment

Because MGD is better and DTS is controlled, the patient should continue all medications and treatment should focus on SLK. Management of the underlying SLK should be based on the severity of the condition using the clinician's preferred treatment options. The patient's IOP should be monitored if topical steroid therapy is continued.

### Case 4

A 53-year-old woman presents for a second opinion regarding her dry eyes.

#### Past medical history

- (1) Rheumatoid arthritis
- (2) Secondary Sjögren syndrome

#### Past ocular history

- (1) 'Significant dry eyes' treated by her ophthalmologist with artificial tears, collagen plugs, and topical cyclosporine (no improvement with cyclosporine after use for 3 weeks)
- (2) Further history taking; patient uses preservative-free artificial tears every 1 to 2 h

#### Examination

- (1) Visual acuity: 20/40 OD; 20/30 OS; cc
- (2) Schirmer test scores: 2 mm OD and 1 mm OS after 5 min without anesthesia
- (3) Lids: 1 to 2+ (mild to moderate) MGD with collarettes, lid debris, and erythema

- (4) Conjunctiva: lissamine green staining consistent with keratoconjunctivitis sicca; no plugs in place
  - (5) Cornea: 2+ (moderate) central fluorescein staining with filaments OU; classic lissamine green staining OU
  - (6) TBUT: 5 s OD; 6 s OS
  - (7) Tear osmolarity (if available): 312 mOsm/l OD; 334 mOsm/l OS
  - (8) MMP-9 is positive OU, confirming inflammation (if available)
- (3) Lids: 1+ (mild) MGD with less erythema OU; no collarettes OU
  - (4) Conjunctiva: 1 to 2+ (mild to moderate) lissamine green staining consistent with keratoconjunctivitis sicca OU
  - (5) Cornea: 1+ (mild) fluorescein staining OU
  - (6) TBUT: 9 s OD; 9 s OS
  - (7) Tear osmolarity (if available): 302 mOsm/l OD; 315 mOsm/l OS

### Diagnosis

This patient has DTS secondary to:

- (1) Moderate aqueous deficiency, with low Schirmer test scores and lissamine green staining consistent with keratoconjunctivitis sicca
- (2) Evaporative dry eye without conjunctival scarring
- (3) Blepharitis (anterior and posterior) with MGD

No DTS co-conspirators are seen.

### Treatment

- (1) Topical anti-inflammatory/immunomodulatory [lifitegrast (5.0%) or cyclosporine (0.05%)] OU twice daily
  - (a) Previous 'failure' was determined to be secondary to using topical cyclosporine for only 3 weeks (too early to determine failure)
  - (b) The patient experienced a '25% improvement' in symptoms and stopped because it was 'not 100%'
- (2) Topical azithromycin (1.0%) OU at bedtime (macrolides have both antibiotic and anti-inflammatory effects)
  - (a) This patient has both anterior (presumed *S. aureus*) and posterior blepharitis
- (3) Warm compresses OU twice daily (beneficial for the MGD)
- (4) Lid cleansers
- (5) Omega-3 nutritional supplements
- (6) Artificial tears (nonpreserved) OU every 2 h (not as needed)
- (7) Follow-up in 4–6 weeks

### Course

Patient presents in 4 weeks stating that she is '40% better' in her DTS symptoms, including improved vision.

### Examination

- (1) Visual acuity: 20/25 OD; 20/20 OS; cc, distance
- (2) Schirmer test scores: 2 mm OD and 3 mm OS after 5 min without anesthesia

### Treatment

- (1) Continue topical anti-inflammatory/immunomodulatory therapy [lifitegrast (5.0%) or cyclosporine (0.05%)] OU twice daily because the patient is definitely better, with improved vision, improved staining, decreased MGD, and improved TBUT, despite only a 40% subjective improvement
- (2) Consider changing topical azithromycin (1.0%) OU at bedtime to a reduced frequency of administration, such as the first 2 weeks of every month
- (3) Place punctal plugs OU lower lids (Schirmer test scores are still decreased)
- (4) Consider starting steroid drops OU twice daily if not started during the last visit
- (5) Consider autologous serum tears if filaments are still present
- (6) Follow-up in 4–6 weeks; may need to have the patient return within 4 weeks to monitor IOP according to the patient's glaucoma risk if a topical steroid is prescribed

Consider NAC if filaments are still present at the next follow-up visit. If the patient has no symptoms and no corneal staining at the next follow-up visit, continue all medications and follow-up in 6 months. If she still has symptoms and/or staining, initiate another treatment option. For example, if Schirmer scores are still low, add upper plugs or topical hormones (topical DHEA or medroxyprogesterone). If Schirmer scores are better but MGD persists, add doxycycline by mouth or doxycycline drops (compounded). If topical steroid drops were included in the treatment regimen at the previous visit, taper over 1–2 weeks.

### Acknowledgements

*The authors thank Kurt Brubaker and MedEdicus for writing and editorial assistance. Responsibility for the content rests with the authors.*

### Author disclosures

*Q.B.A., MD, has had a financial agreement or affiliation during the past year with the following commercial*



interests in the form of Consultant/Advisory Board: Alcon; Allergan; and Bausch & Lomb Incorporated; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Alcon; Allergan; and Bausch & Lomb Incorporated; Ownership Interest: Allergan.

R.M.A., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; and Bausch & Lomb Incorporated; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Alcon; and Bausch & Lomb Incorporated; Ownership Interest: IDOC; and Nanophthalmos, LLC; Patent Holder: IDOC; and Nanophthalmos, LLC.

K.A.B., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Royalty: eyeXpress; Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; eyeXpress; Omeros Corporation; Shire; Sun Pharmaceutical Industries Ltd; and TearLab Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Alcon; Shire; and TearLab Corporation; Ownership Interest: Calhoun Vision, Inc; and Rapid Pathogen Screening, Inc.

J.B., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Envista; Equinox; Omega Ophthalmics; and Vitamed; Ownership Interest: Equinox; and Omega Ophthalmics.

T.S.B., MD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan and Shire.

C.B., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; LENSAR, LLC; and Omeros Corporation; Contracted Research: Allergan; Bausch & Lomb Incorporated; and Glaukos Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; LENSAR, LLC; and Omeros Corporation; Ownership Interest: Calhoun Vision, Inc; CXL Ophthalmics; Glaukos Corporation; and Rapid Pathogen Screening, Inc.

J.P.G., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Shire; Honoraria from promotional, advertising or

non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; and Bausch & Lomb Incorporated.

D.F.G., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Innovision Labs, Inc; Ocular Sciences, Inc; Ocular Therapeutix Inc; and Ora, Inc; Contracted Research: Abbott Laboratories Inc; Aerie Pharmaceuticals, Inc; Alcon; Allergan; Auven Therapeutics; Bausch & Lomb Incorporated; Eleven Biotherapeutics; Kala Pharmaceuticals; Mati Therapeutics, Inc; Ocular Therapeutix Inc; and OCULUS, Inc; Royalty: ALPHAEON Corporation.

D.G., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; Omeros Corporation; and Shire; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Alcon; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; Omeros Corporation; and Shire; Ownership Interest: Allergan; and Ocular Therapeutix Inc.

R.K.G., MD, MPH, has no relevant commercial relationships to disclose.

M.A.J., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Avellino Labs; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Diopsys, Inc; i-optics; LENSAR, LLC; Marco; Ocular Therapeutix, Inc; Omeros Corporation; Paragon BioTeck, Inc; Rapid Pathogen Screening, Inc; ScienceBased Health; Shire; Stemnion; TearLab Corporation; and TearScience; Ownership Interest: Ace Vision Group, Inc; ArcScan; Calhoun Vision, Inc; Paragon BioTeck, Inc; and Rapid Pathogen Screening, Inc.

J.K., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Alimera Sciences; Allergan; Bio-Tissue; CheckedUp; i-Optics; Leica; and TrueVision; Contracted Research: Bausch & Lomb Incorporated; Ocular Therapeutix Inc; and Refocus Group, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Alcon; and Shire; Ownership Interest: TrueVision.

T.K., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Actavis; Acucela Inc; Aerie Pharmaceuticals, Inc; Alcon; Allergan; Avellino Labs; Bausch & Lomb Incorporated; CoDa Therapeutics, Inc; Foresight Biotherapeutics; Kala

Pharmaceuticals; NovaBay Pharmaceuticals, Inc; Ocular Systems, Inc; Ocular Therapeutix Inc; Oculeve Inc; Omeros Corporation; Osiris; PowerVision, Inc; Presbyopia Therapies; Shire; Stealth BioTherapeutics Inc; TearLab Corporation; TearScience; and Valeant; Ownership Interest: Ocular Therapeutix Inc; Omeros Corporation; and TearScience.

J.I.L., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Bausch & Lomb Incorporated; Shire; TearLab Corporation; and Trefoil Therapeutics, LLC; Contracted Research: Alcon; Allergan; Auven Therapeutics; Bausch & Lomb Incorporated; Eleven Biotherapeutics; Refocus Group, Inc; and Shire; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Bausch & Lomb Incorporated; and Shire; Ownership Interest: Calhoun Vision, Inc; CXL Ophthalmics; Insightful Solutions, LLC; Omega Ophthalmics; Rapid Pathogen Screening, Inc; and Trefoil Therapeutics, LLC.

P.A.M., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Shire; TearScience; and Valeant; Contracted Research: Allergan; and Shire; Ownership Interest: Rapid Pathogen Screening, Inc.

R.P.M., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Allergan; Bausch & Lomb Incorporated; BioD, LLC; InSite Vision Incorporated; Katena Products, Inc; Nicox; OASIS Medical; Shire; and TearScience; Contracted Research: Abbott Laboratories Inc; Alcon; Allergan; Bausch & Lomb Incorporated; BioD, LLC; InSite Vision Incorporated; Katena Products, Inc; Nicox; OASIS Medical; Shire; and TearScience; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Alcon; Allergan; Bausch & Lomb Incorporated; BioD, LLC; InSite Vision Incorporated; Katena Products, Inc; Nicox; OASIS Medical; Shire; and TearScience.

M.B.M.D., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Royalty/Patent Holder: CenterVue SpA; Consultant/Advisory Board: Abbott Medical Optics; Alcon; Allergan; Altaire; Bausch & Lomb Incorporated; BelpEx; Bio-Tissue; CenterVue SpA; Focus Laboratories; Naturaceutical Delivery Corporation; OcuSoft; OCULUS, Inc; Optical Express; ORCA Surgical; Perrigo Company plc; Rapid Pathogen Screening, Inc; Shire; TearLab Corporation; TearScience; and Valeant; Honoraria from promotional, advertising or non-CME

services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; Omeros Corporation; ORCA Surgical; Shire; TearLab Corporation; and TearScience; Ownership Interest: Naturaceutical Delivery Corporation; and ORCA Surgical.

M.S.M., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Omeros Corporation; Shire; and Sun Pharmaceutical Industries Ltd; Contracted Research: Eleven Biotherapeutics; EyeGate; and Kala Pharmaceuticals; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Bausch & Lomb Incorporated; Shire; Sun Pharmaceutical Industries Ltd; and TearScience; Ownership Interest: Rapid Pathogen Screening, Inc.

R.K.R., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Salary: Avedro, Inc; Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Mimetogen Pharmaceuticals; Nicox; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; and Valeant; Contracted Research: Abbott Laboratories Inc; Alcon; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Mimetogen Pharmaceuticals; Nicox; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; and Valeant; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Alcon; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Mimetogen Pharmaceuticals; Nicox; Rapid Pathogen Screening, Inc; Santen Pharmaceutical Co, Ltd; Shire; and Valeant; Ownership Interest: Avedro, Inc; Calhoun Vision, Inc; Mimetogen Pharmaceuticals; Rapid Pathogen Screening, Inc; and TearSolutions, Inc.

T.R., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Medical Optics; Glaukos Corporation; and Ocular Therapeutix, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Medical Optics; Bausch & Lomb Incorporated; Glaukos Corporation; Shire; and TearScience.

S.R., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; Imprimis Pharmaceuticals, Inc; Omeros Corporation; Rapid Pathogen Screening, Inc; Shire; and Sun

Pharmaceutical Industries Ltd; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Bausch & Lomb Incorporated; Physician Recommended Nutraceuticals; and Shire.

N.S., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; and Nicox; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Bausch & Lomb Incorporated; Nicox; and Shire.

J.D.S., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; and Bausch & Lomb Incorporated; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Ownership Interest: Rapid Pathogen Screening, Inc.

K.S., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Allergan; ALPHAEON Corporation; Bausch & Lomb Incorporated; Nidek Co, Ltd; Refocus Group, Inc; and Shire; Contracted Research: Alcon; Allergan; Nidek Co, Ltd; Presbia PLC; and Refocus Group, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Alcon; Allergan; Bausch & Lomb Incorporated; Nidek Co, Ltd; Presbia PLC; Refocus Group, Inc; and Shire; Ownership Interest: ALPHAEON Corporation; and Physicians Protocol.

S.T., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Receipt of Intellectual Rights/Patent Holder: Ocugenesis; Consultant/Advisory Board: Abbott Laboratories Inc; Allergan; NovaBay Pharmaceuticals, Inc; and Shire; Ownership Interest: Calhoun Vision, Inc.

W.T., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; and Shire; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Allergan; Bausch & Lomb Incorporated; and NovaBay Pharmaceuticals, Inc; Ownership Interest: ALPHAEON Corporation.

K.A.W., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Royalty/Patent Holder: Ocular Systems, Inc; Consultant/Advisory Board: Abbott

Laboratories Inc; Omeros Corporation; Shire; and Sun Pharmaceuticals Industries Ltd; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Omeros Corporation; Shire; and Sun Pharmaceuticals Industries Ltd; Ownership Interest: Abbott Laboratories Inc; and Omeros Corporation.

G.O.W. IV, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; ACE Vision Group, Inc; AcuFocus, Inc; Alcon; Allergan; Avedro, Inc; Bausch & Lomb Incorporated; Halma plc; Omega Ophthalmics; and Perfect Lens LLC; Royalty: AcuFocus, Inc.

R.J.W., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Bausch & Lomb Incorporated; and Omeros Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Alcon; Allergan; Bausch & Lomb Incorporated; i-Optics; MacuLogix, Inc; Omeros Corporation; Sun Ophthalmics; STAAR Surgical; and TrueVision; Ownership Interest: Calhoun Vision, Inc; DigiHealth; PogoTec; Rapid Pathogen Screening, Inc; TrueVision; and uBeam.

W.F.W., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; AcuFocus, Inc; Alcon; ArcScan, Inc; Bausch & Lomb Incorporated; Calhoun Vision, Inc; Cassini; New World Medical, Inc; Omega Ophthalmics; ReVision Optics, Inc; and Zeiss; Ownership Interest: Equinox; Imprimis Pharmaceuticals, Inc; and Rapid Pathogen Screening, Inc.

E.Y., MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Laboratories Inc; Alcon; Allergan; ArcScan, Inc; Bausch & Lomb Incorporated; Bio-Tissue; EyeKon E.R.D Ltd; i-Optics; Kala Pharmaceuticals Inc; Ocular Therapeutix Inc; OCuSOFT; Shire; TearLab Corporation; TearScience; and Valeant; Contracted Research: ArcScan, Inc; Bio-Tissue; i-Optics; and Topcon Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Abbott Laboratories Inc; Alcon; Allergan; Bio-Tissue; i-Optics; Ocular Therapeutix Inc; Omeros Corporation; Rapid Pathogen Screening, Inc; and Shire; Receipt of Intellectual Rights/Patent Holder: Modernizing Medicine, Inc; Rapid Pathogen Screening, Inc; and Strathspey Crown.

**CME PEER-REVIEWER DISCLOSURE:** Robert Latkany, MD, has had a financial agreement or



affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Shire; Contracted Research: Shire; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (e.g., Speakers Bureaus): Shire.

**EDITORIAL SUPPORT DISCLOSURES:** Kurt Brubaker has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Medical Writing Services: Bausch & Lomb Incorporated; Barbara Aabel; Kimberly Corbin, CHCP; Diane McArdle, PhD; Michelle Ong; and Cynthia Tornallyay, RD, MBA, CHCP, have no relevant commercial relationships to disclose.

## REFERENCES

- Behrens A, Doyle JJ, Stern L, *et al.*, Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. *Cornea* 2006; 25:900–907.
- Begley CG, Chalmers RL, Abetz L, *et al.* The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. *Invest Ophthalmol Vis Sci* 2003; 44:4753–4761.
- Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. *Cornea* 2004; 23:762–770.
- Fiscella RG. Understanding dry eye disease: a managed care perspective. *Am J Manag Care* 2011; 17:S432–S439.
- Donnenfeld ED, Solomon R, Roberts CW, *et al.* Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. *J Cataract Refract Surg* 2010; 36:1095–1100.
- Albietz JM, McLennan SG, Lenton LM. Ocular surface management of photorefractive keratectomy and laser in situ keratomileusis. *J Refract Surg* 2003; 19:636–644.
- Report of the International Dry Eye WorkShop (2007). *Ocul Surf* 2007; 5:69–204.
- Nichols KK, Foulks GN, Bron AJ, *et al.* The International Workshop on Meibomian Gland Dysfunction. *Invest Ophthalmol Vis Sci* 2011; 52:1917–2085.
- American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Dry eye syndrome. San Francisco, CA: American Academy of Ophthalmology; 2013.
- American Academy of Ophthalmology Cornea/External Disease Panel. Preferred practice pattern guidelines. Blepharitis. San Francisco, CA: American Academy of Ophthalmology; 2013.
- Montés-Micó R. Role of the tear film in the optical quality of the human eye. *J Cataract Refract Surg* 2007; 33:1631–1635.
- Bron AJ, Tomlinson A, Foulks GN, *et al.* Rethinking dry eye disease: a perspective on clinical implications. *Ocul Surf* 2014; 12:S1–S31.
- Tomlinson A, Khanal S, Ramaesh K, *et al.* Tear film osmolarity: determination of a referent for dry eye diagnosis. *Invest Ophthalmol Vis Sci* 2006; 47:4309–4315.
- Lemp MA, Bron AJ, Baudouin C, *et al.* Tear osmolarity in the diagnosis and management of dry eye disease. *Am J Ophthalmol* 2011; 151:792.e1–798.e1.
- Savini G, Prabhawat P, Kojima T, *et al.* The challenge of dry eye diagnosis. *Clin Ophthalmol* 2008; 2:31–55.
- Honda M, Miyai T, Nejima R, *et al.* Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. *Arch Ophthalmol* 2010; 128:466–471.
- Chotikavanich S, de Paiva CS, Li de Q, *et al.* Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. *Invest Ophthalmol Vis Sci* 2009; 50:3203–3209.
- InflammaDry [package insert]. Sarasota, FL: Rapid Pathogen Screening, Inc; 2014.
- Pflugfelder SC, Tseng SC, Sanabria O, *et al.* Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. *Cornea* 1998; 17:38–56.
- Manning FJ, Wehrly SR, Foulks GN. Patient tolerance and ocular surface staining characteristics of lissamine green versus rose bengal. *Ophthalmology* 1995; 102:1953–1957.
- Machado LM, Castro RS, Fontes BM. Staining patterns in dry eye syndrome: rose bengal versus lissamine green. *Cornea* 2009; 28:732–734.
- Stern ME, Schaumberg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. *Int Rev Immunol* 2013; 32:19–41.
- Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. *Ocul Surf* 2009; 7:S1–S14.
- Luchs JJ, *et al.* Incidence of blepharitis in patients undergoing phacoemulsification. Poster presented at: ASCRS-ASOA Symposium and Congress; 9–14 April 2010; Boston, Massachusetts, USA.
- Lemp MA, Crews LA, Bron AJ, *et al.* Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. *Cornea* 2012; 31:472–478.
- Mishima S, Gasset A, Klyce SD Jr, Baum JL. Determination of tear volume and tear flow. *Invest Ophthalmol* 1966; 5:264–276.
- Scherz W, Dohlman CH. Is the lacrimal gland dispensable? Keratoconjunctivitis sicca after lacrimal gland removal. *Arch Ophthalmol* 1975; 93:281–283.
- Li DQ, Chen Z, Song XJ, *et al.* Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. *Invest Ophthalmol Vis Sci* 2004; 45:4302–4311.
- Nakamura H, Kawakami A, Eguchi K. Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome. *Transl Res* 2006; 148:281–288.
- Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. *CLAO J* 1995; 21:221–232.
- Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. *Br J Ophthalmol* 1984; 68:674–680.
- Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. *Ophthalmology* 1992; 99:605–617.
- McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. *Ophthalmology* 1982; 89:1173–1180.
- Jackson WB. Blepharitis: current strategies for diagnosis and management. *Can J Ophthalmol* 2008; 43:170–179.
- Tei M, Spurr-Michaud SJ, Tisdale AS, Gipson IK. Vitamin A deficiency alters the expression of mucin genes by the rat ocular surface epithelium. *Invest Ophthalmol Vis Sci* 2000; 41:82–88.
- Shine WE, McCulley JP. The role of cholesterol in chronic blepharitis. *Invest Ophthalmol Vis Sci* 1991; 32:2272–2280.
- Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated *Staphylococcus aureus* growth to chronic blepharitis. *Invest Ophthalmol Vis Sci* 1993; 34:2291–2296.
- Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. *Invest Ophthalmol Vis Sci* 1986; 27:486–491.
- McCulley JP, Shine WE. Meibomian secretions in chronic blepharitis. *Adv Exp Med Biol* 1998; 438:319–326.
- Pflugfelder SC, Tseng SC, Yoshino K, *et al.* Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. *Ophthalmology* 1997; 104:223–235.
- Ralph RA. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. *Invest Ophthalmol* 1975; 14:299–302.
- Bowling B. Kanski's clinical ophthalmology: a systematic approach. 8th ed. Cambridge, MA: Elsevier; 2016.
- Villani E, Baudouin C, Efron N, *et al.* In vivo confocal microscopy of the ocular surface: from bench to bedside. *Curr Eye Res* 2014; 39:213–231.
- Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. *Arch Ophthalmol* 2002; 120:330–337.
- Brignole F, Pisella PJ, De Saint Jean M, *et al.* Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A. *Invest Ophthalmol Vis Sci* 2001; 42:90–95.
- Zhao H, Jumblatt JE, Wood TO, Jumblatt MM. Quantification of MUC5AC protein in human tears. *Cornea* 2001; 20:873–877.
- Doughty MJ. Contact lens wear and the goblet cells of the human conjunctiva – a review. *Cont Lens Anterior Eye* 2011; 34:157–163.
- Lemp MA. Breakup of the tear film. *Int Ophthalmol Clin* 1973; 13:97–102.
- Tsubota K, Nakamori K. Effects of ocular surface area and blink rate on tear dynamics. *Arch Ophthalmol* 1995; 113:155–158.
- Abelson MB, Ousler GW 3rd, Nally LA, *et al.* Alternative reference values for tear film breakup time in normal and dry eye populations. *Adv Exp Med Biol* 2002; 506:1121–1125.
- Latkany RL, Lock B, Speaker M. Nocturnal lagophthalmos: an overview and classification. *Ocul Surf* 2006; 4:44–53.
- Fatfeh S, Rekkerth DJ, Hadley JA. Skin prick/puncture testing in North America: a call for standards and consistency. *Allergy Asthma Clin Immunol* 2014; 10:44.
- Nomura K, Takamura E. Tear IgE concentrations in allergic conjunctivitis. *Eye (Lond)* 1998; 12:296–298.
- Schiffman RM, Christianson MD, Jacobsen G, *et al.* Reliability and validity of the Ocular Surface Disease Index. *Arch Ophthalmol* 2000; 118:615–621.
- Ngo W, Situ P, Keir N, *et al.* Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. *Cornea* 2013; 32:1204–1210.
- Chodosh J, Dix RD, Howell RC, *et al.* Staining characteristics and antiviral activity of sulforhodamine B and lissamine green B. *Invest Ophthalmol Vis Sci* 1994; 35:1046–1058.
- van Bijsterveld OP. Diagnostic tests in the sicca syndrome. *Arch Ophthalmol* 1969; 82:10–14.
- Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. *Cornea* 2003; 22:640–650.



59. Farris RL, Gilbard JP, Stuchell RN, Mandel ID. Diagnostic tests in keratoconjunctivitis sicca. *CLAO J* 1983; 9:23–28.
60. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. *Cornea* 2004; 23:272–285.
61. Sullivan BD, *et al.* IOVS 2010; 51: ARVO E-Abstract 3380.
62. Keech A, Senchyna M, Jones L. Impact of time between collection and collection method on human tear fluid osmolarity. *Curr Eye Res* 2013; 38:428–436.
63. Bunya VY, Langelier N, Chen S, *et al.* Tear osmolarity in Sjögren syndrome. *Cornea* 2013; 32:922–927.
64. Yeh TN, Graham AD, Lin MC. Relationships among tear film stability, osmolarity, and dryness symptoms. *Optom Vis Sci* 2015; 92:e264–e272.
65. Messmer EM, Bulgen M, Kampik A. Hyperosmolarity of the tear film in dry eye syndrome. *Dev Ophthalmol* 2010; 45:129–138.
66. Szalai E, Berta A, Szekanez Z, *et al.* Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system. *Cornea* 2012; 31:867–871.
67. Sambursky R, Davitt WF 3rd, Latkany R, *et al.* Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. *JAMA Ophthalmol* 2013; 131:24–28.
68. Schargus M, Ivanova S, Kakkassery V, *et al.* Correlation of tear film osmolarity and 2 different MMP-9 tests with common dry eye tests in a cohort of nondry eye patients. *Cornea* 2015; 34:739–744.
69. Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. *Cornea* 1996; 15:235–239.
70. Bourcier T, Acosta MC, Borderie V, *et al.* Decreased corneal sensitivity in patients with dry eye. *Invest Ophthalmol Vis Sci* 2005; 46:2341–2345.
71. Labbé A, Liang Q, Wang Z, *et al.* Corneal nerve structure and function in patients with non-Sjögren dry eye: clinical correlations. *Invest Ophthalmol Vis Sci* 2013; 54:5144–5150.
72. Ohashi Y, Ishida R, Kojima T, *et al.* Abnormal protein profiles in tears with dry eye syndrome. *Am J Ophthalmol* 2003; 136:291–299.
73. Zhou L, Beuerman RW, Chan CM, *et al.* Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. *J Proteome Res* 2009; 8:4889–4905.
74. Goren MB, Goren SB. Diagnostic tests in patients with symptoms of keratoconjunctivitis sicca. *Am J Ophthalmol* 1988; 106:570–574.
75. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. *Clin Exp Immunol* 2008; 153:17–21.
76. Mimura T, Usui T, Yamagami S, *et al.* Relation between total tear IgE and severity of acute seasonal allergic conjunctivitis. *Curr Eye Res* 2012; 37:864–870.
77. Tung CI, Perin AF, Gumus K, Pflugfelder SC. Tear meniscus dimensions in tear dysfunction and their correlation with clinical parameters. *Am J Ophthalmol* 2014; 157:301.e1–310.e1.
78. Zeev MS, Miller DD, Latkany R. Diagnosis of dry eye disease and emerging technologies. *Clin Ophthalmol* 2014; 8:581–590.
79. Li M, Du C, Zhu D, *et al.* Daytime variations of tear osmolarity and tear meniscus volume. *Eye Contact Lens* 2012; 38:282–287.
80. Bartuzel MM, Szczesna-Iskander DH, Iskander DR. Automatic dynamic tear meniscus measurement in optical coherence tomography. *Biomed Opt Express* 2014; 5:2759–2768.
81. King-Smith PE, Kimball SH, Nichols JJ. Tear film interferometry and corneal surface roughness. *Invest Ophthalmol Vis Sci* 2014; 55:2614–2618.
82. Finis D, König C, Hayajneh J, *et al.* Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. *Cornea* 2014; 33:1265–1270.
83. Jackson MA. A systematic approach to dry eye using LipiFlow treatment. *US Ophthalmic Rev* 2014; 7:104–108.
84. Ngo W, Srinivasan S, Schulze M, Jones L. Repeatability of grading meibomian gland dropout using two infrared systems. *Optom Vis Sci* 2014; 91:658–667.
85. Shen L, Suresh L, Lindemann M, *et al.* Novel autoantibodies in Sjögren's syndrome. *Clin Immunol* 2012; 145:251–255.
86. Tincani A, Andreoli L, Cavazzana I, *et al.* Novel aspects of Sjögren's syndrome in 2012. *BMC Med* 2013; 11:93.
87. Shen L, Kapsogeorgou EK, Yu M, *et al.* Evaluation of salivary gland protein 1 antibodies in patients with primary and secondary Sjögren's syndrome. *Clin Immunol* 2014; 155:42–46.
88. Gilbard JP, Carter JB, Sang DN, *et al.* Morphologic effect of hyperosmolarity on rabbit corneal epithelium. *Ophthalmology* 1984; 91:1205–1212.
89. Korb DR, Herman JP, Blackie CA, *et al.* Prevalence of lid wiper epitheliopathy in subjects with dry eye signs and symptoms. *Cornea* 2010; 29:377–383.
90. Yokoi N, Yamada H, Mizukusa Y, *et al.* Rheology of tear film lipid layer spread in normal and aqueous tear-deficient dry eyes. *Invest Ophthalmol Vis Sci* 2008; 49:5319–5324.
91. De Paiva CS, Corrales RM, Villarreal AL, *et al.* Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. *Exp Eye Res* 2006; 83:526–535.
92. Moshirfar M, Pierson K, Hanamaikai K, *et al.* Artificial tears potpourri: a literature review. *Clin Ophthalmol* 2014; 8:1419–1433.
93. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. *Surv Ophthalmol* 1980; 25:15–30.
94. Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. *Cornea* 2006; 25:1133–1138.
95. Xu M, Sivak JG, McCanna DJ. Comparison of the effects of ophthalmic solutions on human corneal epithelial cells using fluorescent dyes. *J Ocul Pharmacol Ther* 2013; 29:704–802.
96. Wander AH, Koffler BH. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. *Ocul Surf* 2009; 7:154–162.
97. Lacrisert [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2015.
98. Koffler BH, McDonald M, Nelinson DS; LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. *Eye Contact Lens* 2010; 36:170–176.
99. Luchs JI, Nelinson DS, Macy JI; LAC-07-01 Study Group. Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: findings from a patient registry. *Cornea* 2010; 29:1417–1427.
100. Miljanović B, Trivedi KA, Dana MR, *et al.* Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. *Am J Clin Nutr* 2005; 82:887–893.
101. Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. *Med Sci Monit* 2014; 20:1583–1589.
102. Sheppard JD Jr, Singh R, McClellan AJ, *et al.* Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. *Cornea* 2013; 32:1297–1304.
103. Stern ME, Beuerman RW, Fox RI, *et al.* The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. *Cornea* 1998; 17:584–589.
104. Solomon A, Dursun D, Liu Z, *et al.* Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. *Invest Ophthalmol Vis Sci* 2001; 42:2283–2292.
105. Pflugfelder SC. Antiinflammatory therapy for dry eye. *Am J Ophthalmol* 2004; 137:337–342.
106. Niederkorn JY, Stern ME, Pflugfelder SC, *et al.* Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. *J Immunol* 2006; 176:3950–3957.
107. Restasis [package insert]. Irvine, CA: Allergan, Inc; 2013.
108. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology* 2000; 107:631–639.
109. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen. *Cornea* 2009; 28:1091–1096.
110. Perry HD, Solomon R, Donnenfeld ED, *et al.* Evaluation of topical cyclosporine for the treatment of dry eye disease. *Arch Ophthalmol* 2008; 126:1046–1050.
111. Mah F, Milner M, Yiu S, *et al.* PERSIST: Physician's Evaluation of Restasis Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. *Clin Ophthalmol* 2012; 6:1971–1976.
112. Su MY, Perry HD, Barsam A, *et al.* The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy. *Cornea* 2011; 30:1098–1104.
113. Zhong M, Gadek TR, Bui M, *et al.* Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye. *ACS Med Chem Lett* 2012; 3:203–206.
114. Murphy CJ, Bentley E, Miller PE, *et al.* The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. *Invest Ophthalmol Vis Sci* 2011; 52:3174–3180.
115. Sheppard JD, Torkildsen GL, Lonsdale JD, *et al.*, OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. *Ophthalmology* 2014; 121:475–483.
116. Xiura [package insert]. Lexington, MA: Shire US Inc; 2016.
117. Tauber J, Karpecki P, Latkany R, *et al.*, OPUS-2 Investigators. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. *Ophthalmology* 2015; 122:2423–2431.
118. Holland EJ, Luchs J, Karpecki PM, *et al.* Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). *Ophthalmology*. In press.
119. Donnenfeld ED, Karpecki PM, Majumdar PA, *et al.* Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. *Cornea* 2016; 35:741–748.
120. Mundasad MV, Novack GD, Allgood VE, *et al.* Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. *J Ocul Pharmacol Ther* 2001; 17:173–179.

121. Urashima H, Okamoto T, Takeji Y, *et al*. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated *in vivo* model. *Cornea* 2004; 23:613–619.
122. DIQUAS [package insert]. Emeryville, CA: Santen Pharmaceutical Co, Ltd; 2015.
123. Mucosta [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2011.
124. Sainz De Le Maza Serra M, Simón Castellvi C, Kabbani O. Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis sicca [in Spanish]. *Arch Soc Esp Oftalmol* 2000; 75:751–756.
125. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. *Am J Ophthalmol* 2003; 136:593–602.
126. Pavesio CE, DeCory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. *Br J Ophthalmol* 2008; 92:455–459.
127. Jee D, Park M, Lee HJ, *et al*. Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. *J Cataract Refract Surg* 2015; 41:756–763.
128. Jonisch J, Steiner A, Udell J. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. *Cornea* 2010; 29:723–726.
129. Korb DR, Greiner JV, Glonek T, *et al*. Effect of periocular humidity on the tear film lipid layer. *Cornea* 1996; 15:129–134.
130. Tsubota K. The effect of wearing spectacles on the humidity of the eye. *Am J Ophthalmol* 1989; 108:92–93.
131. Freeman JM. The punctum plug: evaluation of a new treatment for the dry eye. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 1975; 79:O874–O879.
132. Nava-Castaneda A, Tovilla-Canales JL, Rodriguez L, *et al*. Effects of lacrimal occlusion with collagen and silicone plugs on patients with conjunctivitis associated with dry eye. *Cornea* 2003; 22:10–14.
133. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. *Cochrane Database Syst Rev* 2010; CD006775.
134. Horwath-Winter J, Thaci A, Gruber A, Boldin I. Long-term retention rates and complications of silicone punctal plugs in dry eye. *Am J Ophthalmol* 2007; 144:441–444.
135. López-García JS, García-Lozano I, Rivas L, *et al*. Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study. *Acta Ophthalmol* 2014; 92:e22–e29.
136. Liu L, Hartwig D, Harloff S, *et al*. An optimised protocol for the production of autologous serum eyedrops. *Graefes Arch Clin Exp Ophthalmol* 2005; 243:706–714.
137. Tsubota K, Goto E, Fujita H, *et al*. Treatment of dry eye by autologous serum application in Sjögren's syndrome. *Br J Ophthalmol* 1999; 83:390–395.
138. Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. *J Ocul Pharmacol Ther* 2012; 28:479–483.
139. Yoon KC. Use of umbilical cord serum in ophthalmology. *Chonnam Med J* 2014; 50:82–85.
140. Pezzotta S, Del Fante C, Scudeller L, *et al*. Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD. *Bone Marrow Transplant* 2016; doi:10.1038/bmt.2016.221. [Epub ahead of print]
141. Shimmura S, Ueno R, Matsumoto Y, *et al*. Albumin as a tear supplement in the treatment of severe dry eye. *Br J Ophthalmol* 2003; 87:1279–1283.
142. Higuchi A, Ueno R, Shimmura S, *et al*. Albumin rescues ocular epithelial cells from cell death in dry eye. *Curr Eye Res* 2007; 32:83–88.
143. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. *JAMA* 2001; 286:2114–2119.
144. Piwkumsribonruang N, Somboonporn W, Luanratanakorn P, *et al*. Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. *J Med Assoc Thai* 2010; 93:647–652.
145. Sullivan BD, Evans JE, Dana MR, Sullivan DA. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. *Arch Ophthalmol* 2006; 124:1286–1292.
146. Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. *Prog Retin Eye Res* 2012; 31:271–285.
147. Labrie F, Bélanger A, Cusan L, *et al*. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 1997; 82:2396–2402.
148. Sullivan BD, Evans JE, Cermak JM, *et al*. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. *Arch Ophthalmol* 2002; 120:1689–1699.
149. Worda C, Nepp J, Huber JC, Sator MO. Treatment of keratoconjunctivitis sicca with topical androgen. *Maturitas* 2001; 37:209–212.
150. Newsome NA, Gross J. Prevention by medroxyprogesterone of perforation in the alkali-burned rabbit cornea: inhibition of collagenolytic activity. *Invest Ophthalmol Vis Sci* 1977; 16:21–31.
151. Del Rosso JQ, Kirckik L, Gallagher CJ. Comparative efficacy and tolerability of dapson 5% gel in adult versus adolescent females with acne vulgaris. *J Clin Aesthet Dermatol* 2015; 8:31–37.
152. Aczone [package insert]. Irvine, CA: Allergan, Inc; 2015.
153. Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. *Ocul Surf* 2013; 11:259–266.
154. Beckman KA. Detection of early markers of Sjögren syndrome in dry eye patients. *Cornea* 2014; 33:1262–1264.
155. Protopic [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2012.
156. Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. *J Ophthalmic Vis Res* 2014; 9:240–250.
157. Moscovici BK, Holzchuh R, Chiacchio BB, *et al*. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. *Cornea* 2012; 31:945–949.
158. Mukherjee A, Ioannides A, Aslanides I. Comparative evaluation of Comfilcon A and Senofilcon A bandage contact lenses after transepithelial photorefractive keratectomy. *J Optom* 2015; 8:27–32.
159. Hadassah J, Bhuvaneshwari N, Rao U, Sehgal PK. Evaluation of succinylated collagen bandage lenses in corneal healing by the expression of matrix metalloproteinases (MMP-2 and MMP-9) in tear fluid. *Ophthalmic Res* 2009; 42:64–72.
160. Li J, Zhang X, Zheng Q, *et al*. Comparative evaluation of silicone hydrogel contact lenses and autologous serum for the management of Sjögren syndrome-associated dry eye. *Cornea* 2015; 34:1072–1078.
161. Albiets J, Sanfilippo P, Troutbeck R, Lenton LM. Management of filamentary keratitis associated with aqueous-deficient dry eye. *Optom Vis Sci* 2003; 80:420–430.
162. Romero-Rangel T, Stavrou P, Cotter J, *et al*. Gas-permeable scleral contact lens therapy in ocular surface disease. *Am J Ophthalmol* 2000; 130:25–32.
163. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. *Am J Ophthalmol* 2000; 130:33–41.
164. Shepard DS, Razavi M, Stason WB, *et al*. Economic appraisal of the Boston Ocular Surface Prosthesis. *Am J Ophthalmol* 2009; 148:860.e2–868.e2.
165. Jacobs DS, Rosenthal P. Boston scleral prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. *Cornea* 2007; 26:1195–1199.
166. Takahide K, Parker PM, Wu M, *et al*. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2007; 13:1016–1021.
167. Vivino FB, Al-Hashimi I, Khan Z, *et al*. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med* 1999; 159:174–181.
168. Ono M, Takamura E, Shinozaki K, *et al*. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. *Am J Ophthalmol* 2004; 138:6–17.
169. Fox RI, Kontinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. *Clin Immunol* 2001; 101:249–263.
170. Ziment I. Acetylcysteine: a drug that is much more than a mucokinetic. *Biomed Pharmacother* 1988; 42:513–519.
171. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. *Clin Ophthalmol* 2013; 7:1797–1803.
172. Pokupec R, Petricek I, Sikić J, *et al*. Comparison of local acetylcysteine and artificial tears in the management of dry eye syndrome [in Croatian]. *Acta Med Croatica* 2005; 59:337–340.
173. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. *Cornea* 1995; 14:473–484.
174. Meller D, Pauklin M, Thomasen H, *et al*. Amniotic membrane transplantation in the human eye. *Dtsch Arztebl Int* 2011; 108:243–248.
175. Pachigolla G, Prasher P, Di Pascuale MA, *et al*. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens* 2009; 35:172–175.
176. ProKera [package insert]. Doral, FL: Bio-Tissue, Inc; 2015.
177. Suri K, Kosker M, Raber IM, *et al*. Sutureless amniotic membrane ProKera for ocular surface disorders: short-term results. *Eye Contact Lens* 2013; 39:341–347.
178. Khanal S, Tomlinson A, Pearce EI, Simmons PA. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. *Cornea* 2007; 26:175–181.
179. Simmons PA, Vehige JG. Clinical performance of a mid-viscosity artificial tear for dry eye treatment. *Cornea* 2007; 26:294–302.
180. Rieger G. Lipid-containing eye drops: a step closer to natural tears. *Ophthalmologica* 1990; 201:206–212.
181. Korb DR, Scaffidi RC, Greiner JV, *et al*. The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms. *Optom Vis Sci* 2005; 82:594–601.
182. Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the precorneal tear film. *Cont Lens Anterior Eye* 2010; 33:83–87.
183. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. *CLAO J* 1996; 22:209–212.
184. Kheirkhah A, Casas V, Li W, *et al*. Corneal manifestations of ocular demodex infestation. *Am J Ophthalmol* 2007; 143:743–749.

185. Mitra M, Menon GJ, Casini A, *et al.* Tear film lipid layer thickness and ocular comfort after meibomian therapy via latent heat with a novel device in normal subjects. *Eye (Lond)* 2005; 19:657–660.
186. Goto E, Monden Y, Takano Y, *et al.* Treatment of noninflamed obstructive meibomian gland dysfunction by an infrared warm compression device. *Br J Ophthalmol* 2002; 86:1403–1407.
187. Finis D, Hayajneh J, König C, *et al.* Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. *Ocul Surf* 2014; 12:146–154.
188. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. *Cornea* 2010; 29:1145–1152.
189. Gupta PK, *et al.* Outcomes of intense pulsed-light therapy for treatment of evaporative dry-eye disease. Paper presented at: American Society of Cataract and Refractive Surgery/American Society of Ophthalmic Administrators Symposium and Congress; 25–29 April 2014; Boston, MA; Abstract 6388.
190. Toyos R. Intense pulsed light (IPL) therapy for dry eye syndrome: a three year case review evaluating safety and efficacy of the treatment. Paper presented at: 16th ESCRS Winter Meeting; 5 February 2012; Prague, Czech Republic.
191. Toyos R. Intense pulsed light as a treatment for dry-eye disease due to meibomian gland dysfunction. *Invest Ophthalmol Vis Sci* 2013; 54:966.
192. Oleňik A, Jiménez-Alfaro I, Alejandro-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. *Clin Interv Aging* 2013; 8:1133–1138.
193. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Trans Am Ophthalmol Soc* 2008; 106:336–356.
194. Malhotra C, Singh S, Chakma P, Jain AK. Effect of oral omega-3 fatty acid supplementation on contrast sensitivity in patients with moderate meibomian gland dysfunction: a prospective placebo-controlled study. *Cornea* 2015; 34:637–643.
195. Perry HD, Doshi-Carnevale S, Donnenfeld ED, *et al.* Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. *Cornea* 2006; 25:171–175.
196. Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. *Cornea* 2012; 31:1386–1393.
197. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. *J Ocul Pharmacol Ther* 2006; 22:47–53.
198. Valenton MJ, Okumoto M. Toxin-producing strains of *Staphylococcus epidermidis* (albus). Isolates from patients with staphylococcal blepharoconjunctivitis. *Arch Ophthalmol* 1973; 89:186–189.
199. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. *Br J Ophthalmol* 1984; 68:524–528.
200. McCulley JP, Dougherty JM. Bacterial aspect of chronic blepharitis. *Trans Ophthalmol Soc U K* 1986; 105:314–318.
201. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. *Paediatr Respir Rev* 2005; 6:227–235.
202. Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? *J Antimicrob Chemother* 2005; 55:10–21.
203. Igami TZ, Holzchuh R, Osaki TH, *et al.* Oral azithromycin for treatment of posterior blepharitis. *Cornea* 2011; 30:1145–1149.
204. Greene JB, Jeng BH, Fintelman RE, Margolis TP. Oral azithromycin for the treatment of meibomitis. *JAMA Ophthalmol* 2014; 132:121–122.
205. Kashkoul MB, Fazel AJ, Kiyavash V, *et al.* Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. *Br J Ophthalmol* 2015; 99:199–204.
206. John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. *Ann Ophthalmol (Skokie)* 2008; 40:68–74.
207. Haque RM, Torkildsen GL, Brubaker K, *et al.* Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. *Cornea* 2010; 29:871–877.
208. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. *Adv Ther* 2008; 25:858–870.
209. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. *Clin Exp Optom* 2011; 94:200–206.
210. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. *Cornea* 2013; 32:44–53.
211. Luchs J. Azithromycin in DuraSite for the treatment of blepharitis. *Clin Ophthalmol* 2010; 4:681–688.
212. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. *Curr Med Res Opin* 2008; 24:287–296.
213. Lee H, Chung B, Kim KS, *et al.* Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. *Am J Ophthalmol* 2014; 158:1172.e1–1183.e1.
214. Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. *Ophthalmology* 1996; 103:1880–1883.
215. Junk AK, Lukacs A, Kampik A. Topical administration of metronidazole gel as an effective therapy alternative in chronic Demodex blepharitis – a case report [in German]. *Klin Monbl Augenheilkd* 1998; 213:48–50.
216. Salem DA, El-Shazly A, Nabih N, *et al.* Evaluation of the efficacy of oral ivermectin in comparison with ivermectin–metronidazole combined therapy in the treatment of ocular and skin lesions of *Demodex folliculorum*. *Int J Infect Dis* 2013; 17:e343–e347.
217. Sneddon IB. A clinical trial of tetracycline in rosacea. *Br J Dermatol* 1966; 78:649–652.
218. Quarterman MJ, Johnson DW, Abele DC, *et al.* Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. *Arch Dermatol* 1997; 133:49–54.
219. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. *Korean J Ophthalmol* 2005; 19:258–263.
220. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. *Invest Ophthalmol Vis Sci* 1991; 32:2970–2975.
221. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. *Exp Eye Res* 2003; 76:417–420.
222. Souchier M, Joffre C, Grégoire S, *et al.* Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. *Br J Ophthalmol* 2008; 92:819–822.
223. Li DQ, Lokeshwar BL, Solomon A, *et al.* Regulation of MMP-9 production by human corneal epithelial cells. *Exp Eye Res* 2001; 73:449–459.
224. Beardsley RM, De Paiva CS, Power DF, Pflugfelder SC. Desiccating stress decreases apical corneal epithelial cell size – modulation by the metalloproteinase inhibitor doxycycline. *Cornea* 2008; 27:935–940.
225. Frucht-Pery J, Sagi E, Hemo I, Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. *Am J Ophthalmol* 1993; 116:88–92.
226. Zengin N, Tol H, Gündüz K, *et al.* Meibomian gland dysfunction and tear film abnormalities in rosacea. *Cornea* 1995; 14:144–146.
227. Culp B, Scheinfeld N. Rosacea: a review. *P T* 2009; 34:38–45.
228. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. *Curr Opin Ophthalmol* 2004; 15:499–502.
229. Schirra F, Richards SM, Liu M, *et al.* Androgen regulation of lipogenic pathways in the mouse meibomian gland. *Exp Eye Res* 2006; 83:291–296.
230. Akyol-Salman I, Azizi S, Mumcu U, Baykal O. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. *J Ocul Pharmacol Ther* 2010; 26:329–333.
231. Akyol-Salman I, Azizi S, Mumcu UY, *et al.* Comparison of the efficacy of topical N-acetyl-cysteine and a topical steroid-antibiotic combination therapy in the treatment of meibomian gland dysfunction. *J Ocul Pharmacol Ther* 2012; 28:49–52.
232. Gilbard JP, Rossi SR. An electrolyte-based solution that increases corneal glycogen and conjunctival goblet-cell density in a rabbit model for keratoconjunctivitis sicca. *Ophthalmology* 1992; 99:600–604.
233. Argüeso P, Balaran M, Spur-Michaud S, *et al.* Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. *Invest Ophthalmol Vis Sci* 2002; 43:1004–1011.
234. Dohlman CH, Friend J, Kalevar V, *et al.* The glycoprotein (mucus) content of tears from normals and dry eye patients. *Exp Eye Res* 1976; 22:359–365.
235. Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. *Exp Eye Res* 1971; 11:239–250.
236. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. *Cornea* 2008; 27:64–69.
237. Kashima T, Itakura H, Akiyama H, Kishi S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. *Clin Ophthalmol* 2014; 8:1003–1010.
238. Terakado K, Yogo T, Kohara Y, *et al.* Conjunctival expression of the P2Y2 receptor and the effects of 3% diquafosol ophthalmic solution in dogs. *Vet J* 2014; 202:48–52.
239. Hori Y, Spurr-Michaud S, Russo CL, *et al.* Differential regulation of membrane-associated mucins in the human ocular surface epithelium. *Invest Ophthalmol Vis Sci* 2004; 45:114–122.
240. Sommer A, Green WR. Goblet cell response to vitamin A treatment for corneal xerophthalmia. *Am J Ophthalmol* 1982; 94:213–215.
241. Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for the treatment of dry eye syndrome. *Am J Ophthalmol* 2009; 147:206–213.
242. Rajaii F, Prescott C. Management of exposure keratopathy. *EyeNet* 2014; 37–38.
243. Cosar CB, Cohen EJ, Rapuano CJ, *et al.* Tarsorrhaphy: clinical experience from a cornea practice. *Cornea* 2001; 20:787–791.
244. Fahmy AM, Hardten DR. Treating ocular surface disease: new agents in development. *Clin Ophthalmol* 2011; 5:465–472.

## New Strategies for Diagnosis and Treatment of DTS

---

245. Meerovitch K, Torkildsens G, Lonsdale J, *et al.* Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye. *Clin Ophthalmol* 2013; 7:1275–1285.
246. Lewis R, *et al.* Randomized, controlled trial comparing intranasal lacrimal neurostimulation with two control applications for acute tear production in moderate-to-severe dry eye patients. Poster accepted for presentation at: ASCRS Annual Meeting, 6–10 May 2016; New Orleans, LA.
247. Chayet A, *et al.* A nonrandomized, open-label study to evaluate the effect of intranasal lacrimal neurostimulation on tear production in subjects with DED. Poster accepted for presentation at: ASCRS Annual Meeting, 6–10 May 2016; New Orleans, LA.
248. Friedman NJ, Butron K, Robledo N, *et al.* A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. *Clin Ophthalmol* 2016; 10:795–804.



**CME Post Test**

To obtain *AMA PRA Category 1 Credit™* for this activity, complete the CME Post Test by writing the best answer to each CME question in the Answer Box located on the Activity Evaluation/Credit Request form on the following page. Alternatively, you can complete the CME Post Test online at <http://tinyurl.com/DTSCME>.

See detailed instructions at **To Obtain AMA PRA Category 1 Credit™** on page 6.

1. What are the primary subtypes of DED presented in the International DEWS report?

- a) ADDE, EDE, and blepharitis/meibomian gland dysfunction
- b) Blepharitis and ADDE
- c) ADDE and EDE
- d) DTS and lid margin disease

2. According to the DTS Panel approach, DTS can be classified as which of the following subtypes?

- a) Mild, moderate, or severe DTS
- b) Aqueous deficiency and/or evaporative tear disease
- c) Aqueous deficiency, blepharitis/MGD, goblet cell deficiency/mucin deficiency, and/or exposure-related DTS
- d) Lagophthalmos, SLK, and/or superficial punctate keratitis

3. According to the DTS Panel approach for the differential diagnosis of potential DTS, the first step should include all of the following, EXCEPT:

- a) Medical and ocular history
- b) Current and past usage of systemic and ocular medications
- c) Timing, frequency, and severity of symptoms reported by the patient
- d) Family history of glaucoma

4. All of the following are important in the assessment of a patient with potential DTS, EXCEPT:

- a) Evaluation of ocular surface staining
- b) Wave front analysis
- c) Slit-lamp examination
- d) TBUT measurement

5. During the initial portion of the slit-lamp examination of a patient with potential DTS, which aspects of the ocular surface and ocular anatomical structures should be observed in detail?

- a) Angle by gonioscopy
- b) Presence or absence of Bowman haze
- c) Tear film meniscus, lashes for any abnormalities, anterior and posterior lid margins, nature of the meibomian gland secretions, appearance of the puncta, and any anomalies of the conjunctiva and cornea
- d) Endothelial cell count

6. Which of the following factors contribute to an increase in tear film hyperosmolarity?

- a) Decreased aqueous production by the lacrimal gland
- b) Presence of MUC5AC
- c) Decreased aqueous outflow through the trabecular meshwork
- d) Excess vitamin C intake

7. Which of the following diagnostic tests is indicative of inflammation associated with DED/DTS?

- a) Low tear osmolarity of 285 mOsm/L in each eye
- b) Positive MMP-9 test
- c) High number of eosinophils on conjunctival biopsy
- d) Positive India ink stain

8. Testing for serologic biomarkers may aid in the management of DED through:

- a) Earlier detection of all types of DED
- b) Earlier detection and directed treatment of Sjögren syndrome
- c) Confirmation of patient-reported symptoms
- d) Determination if patients are genetically prone to MGD

9. Which of the following is diagnostic for MGD?

- a) Visualization of the meibomian gland via meibography
- b) Decreased tear film meniscus
- c) Poor or partial blink
- d) Schirmer score <10 mm after 5 min

10. According to available evidence, which treatment option for blepharitis/MGD is recommended by the DTS Panel approach for the treatment of anterior blepharitis, in which an infectious component is known or suspected to be part of the etiology?

- a) Topical cyclosporine
- b) Topical *N*-acetylcysteine
- c) Nutritional supplements
- d) Topical antibiotic formulations

11. Which of the following anti-inflammatory agents is indicated for the treatment of DED?

- a) Cefazolin, lifitegrast
- b) Cyclosporine, lifitegrast
- c) Brimonidine, cyclosporine
- d) Levofloxacin, cyclopentolate

12. A 58-year-old woman presents with ocular dryness and discomfort and reported fluctuations in vision. A nonanesthetized Schirmer score of 5 and 7 mm is recorded OD and OS, respectively. Upon examination, reduced tear meniscus and moderate punctate corneal staining is observed following instillation of fluorescein dye. Based on the DTS Panel approach, which of the following is the most likely diagnosis?

- a) Aqueous deficiency
- b) Blepharitis/MGD
- c) Goblet cell deficiency/mucin deficiency
- d) Exposure-related DTS

13. A 65-year-old woman is referred to your clinic with persistent complaints of ocular dryness and irritation associated with reading and driving. A rapid TBUT of 3 s is observed (OU), and upon expression of the meibomian glands, cloudy, thickened secretions are noted. Trace to moderate lid erythema and telangiectasia are noted on the upper and lower lids. Based on the DTS Panel approach, which of the following is the most likely diagnosis?

- a) Aqueous deficiency
- b) Blepharitis/MGD

- c) Goblet cell deficiency/mucin deficiency
- d) Exposure-related DTS

14. A 42-year-old man presents with complaints of ocular dryness and burning associated with using the computer and windy conditions. The patient reports a history of a chemical injury to both eyes 3 years ago and frequent use of preserved artificial tears in an effort to control his symptoms. A rapid TBUT of 3–5 s is observed OD and OS, respectively. Moderate-to-mild conjunctival scarring is noted upon examination. The patient has normal appearing lids and meibomian gland secretions. Based on the DTS Panel approach, which of the following is the most likely diagnosis?

- a) Aqueous deficiency
- b) Blepharitis/MGD
- c) Goblet cell/mucin deficiency
- d) Exposure-related DTS

15. A 72-year-old woman is referred for evaluation because of reported ocular irritation and foreign body sensation (OD). The patient reports frequent irritation in the affected eye upon waking, with the discomfort diminishing, but still present, throughout the day. Moderate-to-severe inferior corneal staining is present following administration of fluorescein. The patient also reports a history of Bell palsy, with a slight partial blink and lagophthalmos OD. Tear breakup time is >10 s OU. Based on the DTS Panel approach, which of the following is the most likely diagnosis?

- a) Aqueous deficiency
- b) Blepharitis/MGD
- c) Goblet cell deficiency/mucin deficiency
- d) Exposure-related DTS

**ACTIVITY EVALUATION/CREDIT REQUEST**

Original Release: January 16, 2017  
 Last Review: November 12, 2016  
 Expiration: January 31, 2018

**Dysfunctional Tear Syndrome: Dry Eye Disease and Associated Tear Film Disorders - New Strategies for Diagnosis and Treatment**

To receive *AMA PRA Category 1 Credit™*, you must complete this **Evaluation** form and the **Post Test**. Record your answers to the **Post Test** in the Answer Box located below. Mail or Fax this completed page to **New York Eye and Ear Infirmary of Mount Sinai–ICME**, 485 Madison Avenue, 17th Floor, New York, NY 10022 (Fax: 212-353-5703). Your comments help us to determine the extent to which this educational activity has met its stated objectives, assess future educational needs, and create timely and pertinent future activities. Please provide all the requested information below. This ensures that your certificate is filled out correctly and is mailed to the proper address. It also enables us to contact you about future CME activities. Please print clearly or type. Illegible submissions cannot be processed.

PARTICIPANT INFORMATION (Please Print)  Home  Office

Last Name \_\_\_\_\_ First Name \_\_\_\_\_  
 Specialty \_\_\_\_\_ Degree  MD  DO  OD  PharmD  RPh  NP  RN  PA  Other \_\_\_\_\_  
 Institution \_\_\_\_\_ Street Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ ZIP Code \_\_\_\_\_ Country \_\_\_\_\_  
 E-mail \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_

**Please note: We do not sell or share e-mail addresses.** They are used strictly for conducting post-activity follow-up surveys to assess the impact of this educational activity on your practice.

**Learner Disclosure:** To ensure compliance with the US Centers for Medicare and Medicaid Services regarding gifts to physicians, **New York Eye and Ear Infirmary of Mount Sinai** Institute for CME requires that you disclose whether or not you have any financial, referral, and/or other relationship with our institution. **CME certificates cannot be awarded unless you answer this question.** For additional information, please call NYEE ICME at 212-979-4383. Thank you.

Yes  No I and/or my family member have a financial relationship with **New York Eye and Ear Infirmary of Mount Sinai** and/or refer Medicare/Medicaid patients to it.

I certify that I have participated in the entire activity and claim 3.0 *AMA PRA Category 1 Credits™*.

Signature Required \_\_\_\_\_ Date Completed \_\_\_\_\_

**OUTCOMES MEASUREMENT**

Yes  No **Did you perceive any commercial bias in any part of this activity? IMPORTANT! If you answered “Yes,” we urge you to be specific about where the bias occurred so we can address the perceived bias with the contributor and/or in the subject matter in future activities.**

Circle the number that best reflects your opinion on the degree to which the following learning objectives were met:  
**5 = Strongly Agree    4 = Agree    3 = Neutral    2 = Disagree    1 = Strongly Disagree**

Upon completion of this activity, I am better able to:

- Outline the potential roles of new diagnostic tests for DTS 5   4   3   2   1
- Discuss recent developments in treatments for DTS 5   4   3   2   1
- Apply available evidence on diagnostic techniques and clinical assessment tools for the differential diagnosis of DTS subtypes 5   4   3   2   1
- Design management plans for patients using treatment modalities that address the underlying disease mechanisms of DTS subtypes 5   4   3   2   1

1. Please list one or more things, if any, you learned from participating in this educational activity that you did not already know.

2. As a result of the knowledge gained in this educational activity, how likely are you to implement changes in your practice?  
**4 = definitely will implement changes    3 = likely will implement changes    2 = likely will not implement any changes    1 = definitely will not make any changes**

Please describe the change(s) you plan to make: 4   3   2   1 \_\_\_\_\_

3. Related to what you learned in this activity, what barriers to implementing these changes or achieving better patient outcomes do you face? \_\_\_\_\_

4. Please check the Core Competencies (as defined by the Accreditation Council for Graduate Medical Education) that were enhanced for you through participation in this activity.

- Patient Care  Practice-Based Learning and Improvement  Professionalism
- Medical Knowledge  Interpersonal and Communication Skills  Systems-Based Practice

5. What other topics would you like to see covered in future CME programs? \_\_\_\_\_

**ADDITIONAL COMMENTS** \_\_\_\_\_

**POST TEST ANSWER BOX**

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15